



Clinical trial results:

A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2012-000126-22 |
| Trial protocol | GB ES |
| Global end of trial date | 03 January 2014 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 08 March 2016 |
| First version publication date | 24 May 2015 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | A18116378 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact | GSK Response Center, GlaxoSmithKline, +1 8664357343, |
| Scientific contact | GSK Response Center, GlaxoSmithKline, +1 8664357343, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 20 March 2014 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 03 September 2013 |
| Global end of trial reached? | Yes |
| Global end of trial date | 03 January 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM.

Protection of trial subjects:

The study design allowed for a long observational period following the first dose to monitor any adverse events (AEs) prior to administration of a second dose. Based on the half-life of the molecule, significant accumulation of drug following the administration of a second dose was not expected. The study had a long follow-up (out to Day 210) to monitor for the appearance of treatment-related AEs.

All participants were rigorously screened by clinical examination for ongoing or potentially emergent infections by a physician at the screening visit, prior to dosing, and during the course of the study. Viral screening methods were employed at screening. Participants who tested positive for any of the following were excluded from the study: Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV).

Participants with current evidence of acute or ongoing infection and a history of repeated, chronic, or opportunistic infections (viral, bacterial, or fungal) were excluded. Where possible, inactivated flu vaccine was administered at screening prior to starting treatment with study medication and in accordance with local practices.

Given the hypothetical role of IL-18 in the potentiation of immune surveillance of nascent tumours, participants with a history of malignancy were excluded from the study.

Eligible women of childbearing potential were allowed to participate in the trial at study sites where regulation allows for their inclusion. They were required to use contraception for approximately 30 weeks after the first dose or up to Study Day 210.

Participants were advised to refrain from travelling to countries where there is a high incidence of infectious diseases until the study follow-up visit on Day 210. By Day 210, the effects on IFN inhibition in the obese population was predicted to be minimal; therefore, little or no impact on the participants' immunity to infection would be anticipated after this time period.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 06 August 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Spain: 37 |
| Worldwide total number of subjects | 37 |
| EEA total number of subjects | 37 |

Notes:

| Subjects enrolled per age group | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 29 |
| From 65 to 84 years | 8 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study consisted of screening and a 4-week treatment period (sponsor-unblinded, placebo-controlled). Obese participants with Type 2 Diabetes Mellitus who remained on their current diet and dose of metformin were enrolled.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Participants received placebo via intravenous (IV) infusion on the Day 1 and Day 29 study visits.

| | |
|--|-----------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Dosing on Days 1 and 29, by 60 minute infusion. Volume matched to active treatment.

| | |
|------------------|-----------------------|
| Arm title | GSK1070806 0.25 mg/kg |
|------------------|-----------------------|

Arm description:

Participants received GSK1070806 0.25 milligrams per kilogram (mg/kg) via IV infusion on the Day 1 and Day 29 study visits.

| | |
|--|-----------------|
| Arm type | Experimental |
| Investigational medicinal product name | GSK1070806 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Dosing on Days 1 and 29, at 0.25 mg/kg, by 60 minute infusion

| | |
|------------------|--------------------|
| Arm title | GSK1070806 5 mg/kg |
|------------------|--------------------|

Arm description:

Participants received GSK1070806 5 mg/kg via IV infusion on the Day 1 and Day 29 study visits.

| | |
|--|-----------------|
| Arm type | Experimental |
| Investigational medicinal product name | GSK1070806 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Dosing on Days 1 and 29, at 5 mg/kg, by 60 minute infusion

| Number of subjects in period 1 | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg |
|---------------------------------------|---------|--------------------------|-----------------------|
| Started | 12 | 13 | 12 |
| Completed | 12 | 13 | 12 |

Baseline characteristics

Reporting groups

| | |
|---|-----------------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Participants received placebo via intravenous (IV) infusion on the Day 1 and Day 29 study visits. | |
| Reporting group title | GSK1070806 0.25 mg/kg |
| Reporting group description: | |
| Participants received GSK1070806 0.25 milligrams per kilogram (mg/kg) via IV infusion on the Day 1 and Day 29 study visits. | |
| Reporting group title | GSK1070806 5 mg/kg |
| Reporting group description: | |
| Participants received GSK1070806 5 mg/kg via IV infusion on the Day 1 and Day 29 study visits. | |

| Reporting group values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg |
|---|---------|-----------------------|--------------------|
| Number of subjects | 12 | 13 | 12 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: years | | | |
| arithmetic mean | 55.1 | 58 | 58.7 |
| standard deviation | ± 9.61 | ± 9.57 | ± 7.97 |
| Gender categorical Units: Subjects | | | |
| Female | 2 | 4 | 3 |
| Male | 10 | 9 | 9 |
| Race, customized Units: Subjects | | | |
| White | 12 | 13 | 12 |

| Reporting group values | Total | | |
|--|-------------|--|--|
| Number of subjects | 37 | | |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) | 0 0 0 | | |

| | | | |
|---|----|--|--|
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 0 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age continuous Units: years arithmetic mean standard deviation | - | | |
| Gender categorical Units: Subjects | | | |
| Female | 9 | | |
| Male | 28 | | |
| Race, customized Units: Subjects | | | |
| White | 37 | | |

End points

End points reporting groups

| | |
|---|-----------------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Participants received placebo via intravenous (IV) infusion on the Day 1 and Day 29 study visits. | |
| Reporting group title | GSK1070806 0.25 mg/kg |
| Reporting group description: | |
| Participants received GSK1070806 0.25 milligrams per kilogram (mg/kg) via IV infusion on the Day 1 and Day 29 study visits. | |
| Reporting group title | GSK1070806 5 mg/kg |
| Reporting group description: | |
| Participants received GSK1070806 5 mg/kg via IV infusion on the Day 1 and Day 29 study visits. | |

Primary: Change from Baseline in fasting plasma glucose (FPG) level on Days 29, 57, and 85

| | |
|---|---|
| End point title | Change from Baseline in fasting plasma glucose (FPG) level on Days 29, 57, and 85 |
| End point description: | |
| The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. Change from Baseline in FPG was compared between treatment groups using repeated measures analysis with fixed effects for Baseline, visit, and Baseline by visit. The Baseline FPG value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. If pre-dose FPG values (laboratory data) were missing, then values were imputed using pre-mixed meal test (MMT) glucose values (biomarker data). | |
| End point type | Primary |
| End point timeframe: | |
| Baseline; Days 29, 57, and 85 | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[1] | 13 ^[2] | 12 ^[3] | |
| Units: Millimoles per liter (mmol/L) | | | | |
| least squares mean (standard error) | | | | |
| Day 29 | -0.047 (± 0.3851) | -0.471 (± 0.3689) | -0.05 (± 0.3799) | |
| Day 57 | -0.755 (± 0.4645) | -0.409 (± 0.4454) | -1.133 (± 0.4603) | |
| Day 85 | -0.555 (± 0.584) | -0.024 (± 0.5604) | -0.591 (± 0.5806) | |

Notes:

[1] - All Subject Population: all participants who received study drug

[2] - All Subject Population: all participants who received study drug

[3] - All Subject Population: all participants who received study drug

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Day 29; Placebo:GSK1070806 0.25 mg/kg |
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.4376 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.424 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.519 |
| upper limit | 0.672 |

| | |
|---|--|
| Statistical analysis title | Day 57; Placebo:GSK1070806 0.25 mg/kg |
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5973 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 0.346 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.975 |
| upper limit | 1.667 |

| | |
|---|--|
| Statistical analysis title | Day 85; Placebo:GSK1070806 0.25 mg/kg |
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5186 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 0.531 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.125 |
| upper limit | 2.186 |

| | |
|---|--|
| Statistical analysis title | Day 29; Placebo:GSK1070806 5 mg/kg |
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.996 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.003 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.103 |
| upper limit | 1.097 |

| | |
|---|--|
| Statistical analysis title | Day 57; Placebo:GSK1070806 5 mg/kg |
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5677 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.378 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.711 |
| upper limit | 0.956 |

| | |
|---|--|
| Statistical analysis title | Day 85; Placebo:GSK1070806 5 mg/kg |
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.9653 |
| Method | Mixed Model Repeated Measures Analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.036 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.713 |
| upper limit | 1.641 |

Primary: Change from Baseline in weighted mean glucose area under the concentration-time curve from time zero (pre-dose) to 4 hours (AUC[0 4hrs]) post-Mixed Meal Test (MMT) on Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in weighted mean glucose area under the concentration-time curve from time zero (pre-dose) to 4 hours (AUC[0 4hrs]) post-Mixed Meal Test (MMT) on Days 29, 57, and 85 |
|-----------------|--|

End point description:

The weighted mean parameters were derived by calculating the area under the curve (AUC, which reflects the actual body exposure to drug after administration of a dose of the drug) using the trapezoidal rule, and then dividing by the actual relevant time interval (i.e., actual time point [hrs] of the first non-missing observation [in planned time $t_f=0$ hour] minus the actual time point [hrs] of the last non-missing observation [e.g., in planned time for glucose, $t_l=240$ minutes]). Change from Baseline in weighted mean AUC(0-4hrs) post-MMT profiles for glucose was compared between treatment groups using repeated measures analysis with fixed effects for Baseline, visit, and Baseline by visit. The Baseline weighted mean glucose value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. If pre-MMT glucose values (biomarker data) were missing, then values were imputed using pre-dose FPG values (laboratory data).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline; Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|-------------------------------------|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[4] | 13 ^[5] | 12 ^[6] | |
| Units: mmol/L | | | | |
| least squares mean (standard error) | | | | |
| Day 29 | 0.09 (± 0.42) | -0.43 (± 0.407) | -0.43 (± 0.407) | |
| Day 57 | -0.47 (± 0.518) | -0.43 (± 0.5) | -1.28 (± 0.508) | |
| Day 85 | -0.48 (± 0.588) | -0.3 (± 0.567) | -0.76 (± 0.579) | |

Notes:

[4] - All Subject Population

[5] - All Subject Population

[6] - All Subject Population

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Day 29

| | |
|-------------------|---------------------------------|
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
|-------------------|---------------------------------|

| | |
|---|--------------------------------|
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.75 |
| upper limit | 0.71 |

| | |
|---|---------------------------------|
| Statistical analysis title | Statistical analysis 2 |
| Statistical analysis description: Day 57 | |
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 0.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.46 |
| upper limit | 1.53 |

| | |
|---|---------------------------------|
| Statistical analysis title | Statistical analysis 3 |
| Statistical analysis description: Day 85 | |
| Comparison groups | Placebo v GSK1070806 0.25 mg/kg |
| Number of subjects included in analysis | 25 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 0.19 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.5 |
| upper limit | 1.87 |

| | |
|---|------------------------|
| Statistical analysis title | Statistical analysis 4 |
| Statistical analysis description: Day 29 | |

| | |
|---|--------------------------------|
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.7 |
| upper limit | 0.67 |

| | |
|---|--------------------------------|
| Statistical analysis title | Statistical analysis 5 |
| Statistical analysis description: Day 57 | |
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.81 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.28 |
| upper limit | 0.66 |

| | |
|---|--------------------------------|
| Statistical analysis title | Statistical analysis 6 |
| Statistical analysis description: Day 85 | |
| Comparison groups | Placebo v GSK1070806 5 mg/kg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.28 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.95 |
| upper limit | 1.39 |

Secondary: Number of participants with any adverse event (AE) and any serious adverse event (SAE)

| | |
|--|--|
| End point title | Number of participants with any adverse event (AE) and any serious adverse event (SAE) |
| End point description: An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect. | |
| End point type | Secondary |
| End point timeframe: From Baseline until follow-up (up to Study Day 210) | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|-----------------------------|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[7] | 13 ^[8] | 12 ^[9] | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| Any AE | 11 | 12 | 11 | |
| Any SAE | 1 | 0 | 1 | |

Notes:

[7] - All Subject Population (ASP)

[8] - All Subject Population (ASP)

[9] - All Subject Population (ASP)

Statistical analyses

No statistical analyses for this end point

Secondary: Albumin and total protein values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|---|--|
| End point title | Albumin and total protein values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
| End point description: Albumin and total protein values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up. | |
| End point type | Secondary |
| End point timeframe: Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210) | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[10] | 13 ^[11] | 12 ^[12] | |
| Units: Grams per liter (G/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Albumin, Screening, n=12, 13, 12 | 47.1 (± 4.62) | 45.9 (± 3.33) | 45.4 (± 2.64) | |

| | | | |
|---|---------------|---------------|---------------|
| Albumin, Day 1: pre-dose, n=12, 12, 12 | 44.7 (± 3.42) | 43.3 (± 3.14) | 45 (± 2.59) |
| Albumin, Day 1: 4 hr, n=11, 12, 11 | 42 (± 4.98) | 42.5 (± 3.68) | 42.4 (± 2.25) |
| Albumin, Day 4, n=11, 12, 11 | 46.8 (± 3.31) | 44.9 (± 2.06) | 45.6 (± 2.87) |
| Albumin, Day 9, n=12, 13, 12 | 46.4 (± 3.53) | 45.2 (± 2.13) | 44.8 (± 3.17) |
| Albumin, Day 14, n=12, 13, 12 | 47.1 (± 4.29) | 44.7 (± 2.78) | 44.8 (± 2.69) |
| Albumin, Day 21, n=12, 13, 12 | 45.9 (± 4.19) | 44.6 (± 2.57) | 45.3 (± 2.93) |
| Albumin, Day 29: pre-dose, n=11, 13, 12 | 44.6 (± 4.25) | 44 (± 4.22) | 44.9 (± 2.97) |
| Albumin, Day 29: 4 hr, n=12, 10, 11 | 42.5 (± 3.18) | 42.3 (± 5.6) | 42.2 (± 2.86) |
| Albumin, Day 32: n=11, 13, 12 | 46.5 (± 2.91) | 45.5 (± 2.85) | 45.3 (± 2.86) |
| Albumin, Day 42: n=12, 13, 12 | 46.7 (± 2.81) | 44.8 (± 2.42) | 46 (± 2.63) |
| Albumin, Day 57: n=12, 13, 12 | 45.7 (± 2.53) | 44.2 (± 3.89) | 45.7 (± 2.19) |
| Albumin, Day 85: n=11, 12, 12 | 45.4 (± 3.29) | 45.8 (± 3.01) | 45.3 (± 2.56) |
| Albumin, Day 120: n=11, 13, 12 | 46 (± 2.9) | 44.5 (± 2.96) | 45 (± 3.3) |
| Albumin, Day 165: n=12, 12, 12 | 45.5 (± 3.06) | 44.8 (± 2.49) | 44.1 (± 3.5) |
| Albumin, follow-up: n=12, 12, 12 | 45.6 (± 3.4) | 44.1 (± 3.12) | 44.3 (± 1.86) |
| Total protein, Screening: n=12, 13, 12 | 73.3 (± 4.79) | 72.3 (± 4.4) | 72.1 (± 4.96) |
| Total protein, Day 1: pre-dose, n=12, 12, 12 | 69.8 (± 4.3) | 69.4 (± 5.04) | 70.6 (± 3.99) |
| Total protein, Day 1: 4 hr, n=11, 12, 11 | 66.3 (± 7.77) | 67.8 (± 3.79) | 67.5 (± 3.56) |
| Total protein, Day 4: n=11, 13, 11 | 73.5 (± 4.82) | 70.2 (± 2.48) | 71.2 (± 4.9) |
| Total protein, Day 9: n=12, 13, 12 | 72.7 (± 4.5) | 70.3 (± 2.9) | 71.7 (± 5.14) |
| Total protein, Day 14: n=12, 13, 12 | 73.6 (± 4.85) | 70.2 (± 3.35) | 71.7 (± 5.79) |
| Total protein, Day 21: n=12, 13, 12 | 71.7 (± 4.03) | 70.2 (± 3.06) | 71.3 (± 4.52) |
| Total protein, Day 29: pre-dose, n=11, 13, 12 | 70 (± 6.87) | 68.5 (± 5.98) | 70.3 (± 5) |
| Total protein, Day 29: 4 hr, n=12, 10, 11 | 67.1 (± 5.68) | 67.3 (± 6) | 65.9 (± 4.93) |
| Total protein, Day 32: n=11, 13, 12 | 72.4 (± 3.64) | 71.5 (± 2.44) | 71.3 (± 3.82) |
| Total protein, Day 42: n=12, 13, 12 | 72.8 (± 4.15) | 70.2 (± 2.45) | 70.9 (± 4.38) |
| Total protein, Day 57: n=12, 13, 12 | 72 (± 2.73) | 68.5 (± 5.58) | 71.1 (± 4.25) |
| Total protein, Day 85: n=11, 12, 12 | 72.1 (± 2.91) | 71.3 (± 5.3) | 70.3 (± 4.96) |
| Total protein, Day 120: n=11, 13, 12 | 73.3 (± 4.47) | 70.2 (± 3.21) | 71 (± 5.44) |
| Total protein, Day 165: n=12, 12, 12 | 72.3 (± 2.96) | 70.8 (± 3.36) | 70.5 (± 5.14) |
| Total protein, follow-up: n=12, 11, 12 | 73.2 (± 4.11) | 69.9 (± 3.59) | 70.8 (± 3.67) |

Notes:

[10] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[11] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[12] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: ALP, ALT, AST, and GGT values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (FU)

| | |
|-----------------|--|
| End point title | ALP, ALT, AST, and GGT values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (FU) |
|-----------------|--|

End point description:

Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transferase (GGT) values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[13] | 13 ^[14] | 12 ^[15] | |
| Units: International Units per liter (IU/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| ALP, Screening, n=12, 13, 12 | 78.5 (± 23.65) | 66.8 (± 13.39) | 76.6 (± 25.72) | |
| ALP, Day 1: pre-dose, n= 12, 12, 12 | 74.5 (± 22.15) | 63.7 (± 17.03) | 69.9 (± 20.08) | |
| ALP, Day 1: 4 hr, n=11, 12, 11 | 71.4 (± 22.01) | 62.9 (± 12.67) | 68.5 (± 23.11) | |
| ALP, Day 4, n=11, 13, 11 | 83.4 (± 27.58) | 64.2 (± 14.29) | 73.6 (± 21.64) | |
| ALP, Day 9, n=12, 13, 12 | 79.6 (± 25.45) | 66.2 (± 14.28) | 70.2 (± 18.5) | |
| ALP, Day 14, n=12, 13, 12 | 79.3 (± 23.26) | 62.1 (± 14.74) | 71.9 (± 19.72) | |
| ALP, Day 21, n=12, 13, 12 | 77.1 (± 22.92) | 63.7 (± 12.4) | 74.9 (± 23.38) | |
| ALP, Day 29: pre-dose, n=11, 13, 12 | 74 (± 25.25) | 63.5 (± 16.61) | 74.3 (± 24.73) | |
| ALP, Day 29: 4 hr, n=12, 10, 11 | 72.8 (± 20.77) | 57.1 (± 12.93) | 71.7 (± 25.78) | |
| ALP, Day 32, n=11, 13, 12 | 83.4 (± 24.43) | 64.2 (± 12.84) | 75.5 (± 26.22) | |
| ALP, Day 42, n=12, 13, 12 | 80.4 (± 22.91) | 61.3 (± 12.05) | 71.7 (± 23) | |
| ALP, Day 57, n=12, 13, 12 | 78.1 (± 23.54) | 59.8 (± 12.07) | 70 (± 17.66) | |
| ALP, Day 85, n=11,12, 12 | 79.8 (± 20.85) | 66.7 (± 12.46) | 69.7 (± 19.12) | |
| ALP, Day 120, n=11, 13, 12 | 75 (± 21.67) | 65.8 (± 13.86) | 72.8 (± 20.97) | |
| ALP, Day 165, n=12, 12, 12 | 79.5 (± 23.73) | 62.1 (± 13.12) | 69.7 (± 20.22) | |
| ALP, follow-up, n=12, 12, 12 | 81.8 (± 22.68) | 64.3 (± 16.74) | 74.1 (± 18.88) | |
| ALT, Screening, n=12, 13, 12 | 34.3 (± 21.24) | 27.9 (± 20.73) | 28.4 (± 13.14) | |
| ALT, Day 1: pre-dose, n=12, 12, 12 | 30.7 (± 19.78) | 26.3 (± 13.14) | 26.2 (± 12.68) | |
| ALT, Day 1: 4 hr, n=11, 12, 11 | 29.4 (± 20.58) | 28.6 (± 18.56) | 26.5 (± 11.83) | |
| ALT, Day 4, n=11, 13, 11 | 32.2 (± 24.06) | 29.6 (± 18.04) | 27.4 (± 14.32) | |
| ALT, Day 9, n=12, 13, 12 | 31.8 (± 22.03) | 26.3 (± 18.21) | 25.7 (± 11.26) | |
| ALT, Day 14, n=12, 13, 12 | 30.3 (± 17.57) | 25.5 (± 14.23) | 29.9 (± 16.47) | |
| ALT, Day 21, n=12, 13, 12 | 29.3 (± 15.51) | 25.7 (± 15.62) | 31.3 (± 20.44) | |
| ALT, Day 29: pre-dose, n=11, 13, 12 | 26.7 (± 15.25) | 25.4 (± 15.44) | 28 (± 20.1) | |
| ALT, Day 29: 4 hr, n=12, 10, 11 | 25.8 (± 15) | 24.5 (± 15.15) | 26 (± 19.88) | |
| ALT, Day 32, n=11, 13, 12 | 29.2 (± 17.53) | 26.2 (± 15.36) | 27.7 (± 16.14) | |
| ALT, Day 42, n=12, 13, 12 | 26.3 (± 12.91) | 25.2 (± 16.05) | 21.6 (± 9.95) | |
| ALT, Day 57, n=12, 13, 12 | 27.8 (± 16.27) | 27.1 (± 23.17) | 24.1 (± 12.09) | |
| ALT, Day 85, n=11, 12, 12 | 23.6 (± 13.97) | 28.3 (± 19.11) | 22.3 (± 12.14) | |
| ALT, Day 120, n=11, 13, 12 | 28.3 (± 17.23) | 27.2 (± 20) | 24.1 (± 11.45) | |
| ALT, Day 165, n=12, 12, 12 | 25.8 (± 15.01) | 28.3 (± 16.74) | 29.8 (± 16.82) | |
| ALT, follow-up, n=12, 12, 12 | 28.8 (± 20.26) | 27.7 (± 16.29) | 26.2 (± 19.69) | |
| AST, Screening, n=12, 13, 12 | 28.3 (± 15.52) | 23.1 (± 7.64) | 30.3 (± 22.34) | |
| AST, Day 1: pre-dose, n=12, 12, 12 | 24.3 (± 11.24) | 23.4 (± 6.57) | 32.3 (± 22.5) | |
| AST, Day 1: 4 hr, n= 11, 12, 11 | 23.5 (± 12.19) | 25.5 (± 11.71) | 32.1 (± 20.6) | |
| AST, Day 4, n=11, 13, 11 | 26.9 (± 15.48) | 28 (± 12.32) | 29.3 (± 16.55) | |
| AST, Day 9, n=12, 13, 12 | 25.1 (± 11.58) | 24.1 (± 11.15) | 26.8 (± 12.74) | |
| AST, Day 14, n=12, 13, 12 | 23.8 (± 9.04) | 23.4 (± 7.26) | 31.3 (± 14.26) | |
| AST, Day 21, n=12, 13, 12 | 24 (± 8.34) | 24.1 (± 11.51) | 30.3 (± 15.99) | |
| AST, Day 29: pre-dose, n=11, 13, 12 | 23.9 (± 10.82) | 24.5 (± 8.88) | 26.8 (± 11.17) | |

| | | | |
|-------------------------------------|-----------------|----------------|----------------|
| AST, Day 29: 4 hr, n=12, 10, 11 | 23.3 (± 10.69) | 25.6 (± 10.89) | 24.3 (± 12.55) |
| AST, Day 32, n=11, 13, 12 | 25.6 (± 12.08) | 26.5 (± 15.15) | 26.1 (± 11.16) |
| AST, Day 42, n=12, 13, 12 | 23.5 (± 8.57) | 24.8 (± 11.04) | 23.1 (± 7.22) |
| AST, Day 57, n=12, 13, 12 | 23.5 (± 8.03) | 27.2 (± 16.27) | 26.4 (± 10.79) |
| AST, Day 85, n=11, 12, 12 | 22 (± 7.04) | 27.2 (± 12.3) | 25.3 (± 9.39) |
| AST, Day 120, n=11, 13, 12 | 24.7 (± 10.2) | 27.8 (± 14.05) | 25.5 (± 8.12) |
| AST, Day 165, n=12, 12, 11 | 21.8 (± 7.31) | 27.7 (± 16.04) | 29.3 (± 15.43) |
| AST, follow-up, n=12, 12, 12 | 23 (± 9.89) | 30.2 (± 26.01) | 30.6 (± 20.18) |
| GGT, Screening, n=12, 13, 12 | 82.4 (± 91.07) | 54.5 (± 44.72) | 67.1 (± 78.69) |
| GGT, Day 1: pre-dose, n=12, 12, 12 | 77.4 (± 93.11) | 51.3 (± 49.89) | 56.6 (± 63.91) |
| GGT, Day 1: 4 hr, n=11, 12, 11 | 75.1 (± 92.04) | 51.5 (± 40.97) | 58.1 (± 64.05) |
| GGT, Day 4, n=11, 13, 11 | 83.3 (± 114.1) | 49.3 (± 39.21) | 59.4 (± 59.95) |
| GGT, Day 9, n=12, 13, 12 | 79.3 (± 98.99) | 47.3 (± 37.47) | 53.8 (± 54.12) |
| GGT, Day 14, n=12, 13, 12 | 81.3 (± 104.94) | 45.3 (± 34.15) | 58.8 (± 70.41) |
| GGT, Day 21, n=12, 13, 12 | 78.4 (± 102.85) | 46.8 (± 34.7) | 60.6 (± 76.89) |
| GGT, Day 29: pre-dose, n=11, 13, 12 | 77.4 (± 86.33) | 45.4 (± 34.77) | 61.8 (± 78.46) |
| GGT, Day 29: 4 hr, n=12, 10, 11 | 67.4 (± 79.37) | 38.5 (± 30.31) | 61.9 (± 86.34) |
| GGT, Day 32, n=11, 13, 12 | 79.1 (± 87.28) | 45.5 (± 33.09) | 63.6 (± 80.35) |
| GGT, Day 42, n=12, 13, 12 | 74.1 (± 87.81) | 43.2 (± 30.1) | 58.8 (± 69.92) |
| GGT, Day 57, n=12, 13, 12 | 74.8 (± 84.94) | 43 (± 30.35) | 63.9 (± 87.39) |
| GGT, Day 85, n=11, 12, 12 | 76 (± 78.73) | 50.7 (± 36.28) | 54.8 (± 58.61) |
| GGT, Day 120, n=11, 13, 12 | 76.5 (± 99.72) | 51.8 (± 45.21) | 55 (± 45.87) |
| GGT, Day 165, n=12, 12, 12 | 68.1 (± 72.82) | 54.2 (± 46.06) | 54.3 (± 36.98) |
| GGT, follow-up, n=12, 12, 12 | 81.5 (± 113.46) | 52.4 (± 44.69) | 51.5 (± 44.76) |

Notes:

[13] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[14] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[15] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Total bilirubin (TB), direct bilirubin (DB), uric acid, and creatinine values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Total bilirubin (TB), direct bilirubin (DB), uric acid, and creatinine values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

TB, DB, uric acid, and creatinine were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[16] | 13 ^[17] | 12 ^[18] | |
| Units: Micromoles per liter (µmol/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| TB, Screening, n=12, 13, 12 | 11.4 (± 5.18) | 12.3 (± 9.45) | 12.5 (± 4.91) | |
| TB, Day 1: pre-dose, n=12, 12, 12 | 10.6 (± 3.63) | 12 (± 10.13) | 10.6 (± 4.5) | |
| TB, Day 1: 4 hr, n= 11, 12, 11 | 10.4 (± 4.7) | 12.8 (± 9.29) | 11.5 (± 6.41) | |
| TB, Day 4, n=11, 13, 11 | 9.7 (± 3.41) | 13.1 (± 8.87) | 10.8 (± 4.94) | |
| TB, Day 9, n=12, 13, 12 | 11.1 (± 4.62) | 11.6 (± 7.63) | 11.4 (± 6.43) | |
| TB, Day 14, n=12, 13, 12 | 9.8 (± 3.89) | 9.5 (± 4.98) | 9.3 (± 3.42) | |
| TB, Day 21, n=12, 13, 12 | 10.6 (± 4.06) | 11.2 (± 6.79) | 9.1 (± 4.19) | |
| TB, Day 29: pre-dose, n=11, 13, 12 | 10.5 (± 4.74) | 9.8 (± 6.92) | 8 (± 3.72) | |
| TB, Day 29: 4 hr, n=12, 10, 11 | 9.3 (± 4.67) | 11.2 (± 6.56) | 9 (± 3.46) | |
| TB, Day 32, n=11, 13, 12 | 10.8 (± 4.62) | 10.2 (± 5.51) | 10.4 (± 3.96) | |
| TB, Day 42, n=12, 13, 12 | 9.4 (± 2.61) | 10.6 (± 5.42) | 9.7 (± 3.94) | |
| TB, Day 57, n=12, 13, 12 | 9.7 (± 4.25) | 9.4 (± 5.84) | 10.3 (± 4.9) | |
| TB, Day 85, n=11, 12, 12 | 10.4 (± 4.13) | 10.3 (± 8.55) | 9.2 (± 3.86) | |
| TB, Day 120, n=11, 13, 12 | 9.9 (± 4.87) | 11.1 (± 7.86) | 10.3 (± 3.52) | |
| TB, Day 165, n=12, 12, 12 | 12.3 (± 5.12) | 12.4 (± 10.08) | 9.6 (± 4.17) | |
| TB, follow-up, n=12, 11, 12 | 10.5 (± 3.9) | 9.7 (± 5.88) | 11.4 (± 5.37) | |
| DB, Screening, n=12, 13, 12 | 2.3 (± 1.14) | 2.4 (± 1.39) | 2.5 (± 1.09) | |
| DB, Day 1: pre-dose, n=12, 12, 12 | 2.2 (± 0.94) | 2.2 (± 1.47) | 2.3 (± 1.07) | |
| DB, Day 1: 4 hr, n=11, 12, 11 | 2.3 (± 1.1) | 2.3 (± 0.97) | 2.4 (± 1.12) | |
| DB, Day 4, n=11, 13, 11 | 2.1 (± 0.7) | 2.5 (± 1.33) | 2.4 (± 1.12) | |
| DB, Day 9, n=12, 13, 12 | 2.3 (± 1.14) | 2.5 (± 1.33) | 2.5 (± 1.45) | |
| DB, Day 14, n=12, 13, 12 | 2.2 (± 1.03) | 1.8 (± 1.07) | 2.3 (± 0.89) | |
| DB, Day 21, n=12, 13, 12 | 2.1 (± 1.08) | 2.3 (± 1.11) | 1.9 (± 0.79) | |
| DB, Day 29: pre-dose, n=11, 13, 12 | 2.3 (± 1.01) | 2 (± 1.29) | 1.6 (± 0.79) | |
| DB, Day 29: 4 hr, n=12, 10, 11 | 1.8 (± 0.83) | 2.5 (± 0.97) | 1.8 (± 0.98) | |
| DB, Day 32, n=11, 13, 12 | 2.4 (± 1.03) | 2.1 (± 0.95) | 2.1 (± 0.9) | |
| DB, Day 42, n=12, 13, 12 | 1.9 (± 0.79) | 2.4 (± 1.19) | 2.1 (± 0.79) | |
| DB, Day 57, n=12, 13, 12 | 1.8 (± 0.97) | 1.9 (± 1.04) | 2.2 (± 0.94) | |
| DB, Day 85, n=11, 12, 12 | 2.1 (± 0.83) | 1.9 (± 1.44) | 1.9 (± 1) | |
| DB, Day 120, n=11, 13, 12 | 2.1 (± 1.22) | 2.3 (± 1.44) | 2.2 (± 0.94) | |
| DB, Day 165, n=12, 12, 12 | 2.2 (± 1.19) | 2.3 (± 1.72) | 2.2 (± 1.19) | |
| DB, follow-up, n=12, 12, 12 | 2.2 (± 0.94) | 1.8 (± 1.14) | 2.5 (± 1.45) | |
| Uric acid, Screening, n=12, 13, 12 | 383.4 (± 90.22) | 343.2 (± 45.25) | 403.7 (± 141.38) | |
| Uric acid, Day 1: pre-dose, n=12, 12, 12 | 354.6 (± 69.19) | 317.3 (± 48.27) | 367.3 (± 115.15) | |
| Uric acid, Day 1: 4 hr, n=11, 12, 11 | 345.1 (± 76.77) | 337.1 (± 44.8) | 374.6 (± 113.7) | |
| Uric acid, Day 4, n=11, 13, 11 | 378.9 (± 73.68) | 339.2 (± 53.7) | 342.5 (± 70.47) | |
| Uric acid, Day 9, n=12, 13, 12 | 394.8 (± 72.25) | 327.5 (± 54.67) | 362.1 (± 113.01) | |
| Uric acid, Day 14, n=12, 13, 12 | 371.5 (± 73.76) | 329.7 (± 38.12) | 359.3 (± 106.74) | |
| Uric acid, Day 21, n=12, 13, 12 | 377.4 (± 86.41) | 349.4 (± 51.24) | 369.9 (± 96.93) | |
| Uric acid, Day 29: pre-dose, n=11, 13, 12 | 373.8 (± 73.15) | 318.2 (± 65.52) | 351.3 (± 71.56) | |

| | | | | |
|--|------------------|------------------|------------------|--|
| Uric acid, Day 29: 4 hr, n=12, 10, 11 | 377.7 (± 70.13) | 335.2 (± 72.78) | 369.2 (± 74.77) | |
| Uric acid, Day 32, n=11, 13, 12 | 363.9 (± 61.45) | 338.5 (± 49.29) | 360 (± 98.91) | |
| Uric acid, Day 42, n=12, 13, 12 | 360.3 (± 66.93) | 339.1 (± 49.42) | 375.1 (± 107.18) | |
| Uric acid, Day 57, n=12, 13, 12 | 378.5 (± 70.18) | 342.3 (± 72.58) | 368.2 (± 97.41) | |
| Uric acid, Day 85, n=11, 12, 12 | 389.6 (± 75.62) | 360.3 (± 57.89) | 382.2 (± 86.89) | |
| Uric acid, Day 120, n=11, 13, 12 | 387.1 (± 73.72) | 348.7 (± 60.3) | 408.2 (± 133.75) | |
| Uric acid, Day 165, n=12, 12, 12 | 389.3 (± 92.6) | 336 (± 52.75) | 388.9 (± 118.78) | |
| Uric acid, follow-up, n=12, 12, 12, | 375.3 (± 69.54) | 351.7 (± 58.99) | 400.3 (± 96.21) | |
| Creatinine, Screening, n=12, 13, 12 | 79.25 (± 12.629) | 66.7 (± 22.865) | 84.45 (± 36.172) | |
| Creatinine, Day 1: pre-dose, n=12, 12, 12 | 72.76 (± 9.329) | 58.76 (± 21.306) | 74.5 (± 29.48) | |
| Creatinine, Day 1: 4 hr, n=11, 12, 11 | 73.75 (± 13.953) | 70.83 (± 20.913) | 86.65 (± 36.271) | |
| Creatinine, Day 4, n=11, 13, 11 | 80.42 (± 13.807) | 65.68 (± 21.55) | 73.27 (± 23.152) | |
| Creatinine, Day 9, n=12, 13, 12 | 78.53 (± 9.959) | 67.18 (± 27.883) | 81.54 (± 38.35) | |
| Creatinine, Day 14, n=12, 13, 12 | 78.38 (± 8.858) | 68.25 (± 22.215) | 76.5 (± 30.091) | |
| Creatinine, Day 21, n=12, 13, 12 | 78.79 (± 11.323) | 67.54 (± 23.637) | 76.13 (± 23.563) | |
| Creatinine, Day 29: pre-dose, n=11, 13, 12 | 75.26 (± 14.326) | 63.05 (± 23.346) | 70.58 (± 18.802) | |
| Creatinine, Day 29: 4 hr, n=12, 10, 11 | 80.6 (± 11.768) | 64.69 (± 13.575) | 83.14 (± 24.275) | |
| Creatinine, Day 32, n=11, 13, 12 | 78.19 (± 13.893) | 69.72 (± 21.132) | 73.79 (± 23.517) | |
| Creatinine, Day 42, n=12, 13, 12 | 79.58 (± 11.309) | 67.9 (± 21.074) | 76.68 (± 21.286) | |
| Creatinine, Day 57, n=12, 13, 12 | 79.43 (± 12.603) | 62.82 (± 21.557) | 72.2 (± 20.543) | |
| Creatinine, Day 85, n=12, 12, 12 | 77.98 (± 9.552) | 65.96 (± 23.705) | 73.3 (± 19.516) | |
| Creatinine, Day 120, n=11, 13, 12 | 81.96 (± 11.361) | 68.87 (± 22.896) | 77.58 (± 20.079) | |
| Creatinine, Day 165, n=12, 12, 12 | 83.46 (± 10.87) | 71.09 (± 31.678) | 76.02 (± 19.963) | |
| Creatinine, follow-up, n=12, 12, 12 | 82.77 (± 11.985) | 72.35 (± 29.601) | 80.14 (± 22.997) | |

Notes:

[16] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[17] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[18] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Potassium, glucose, calcium, cholesterol, HDL, LDL, chloride, creatinine, sodium, triglycerides, and urea/BUN values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and

165; and FU

| | |
|-----------------|---|
| End point title | Potassium, glucose, calcium, cholesterol, HDL, LDL, chloride, creatinine, sodium, triglycerides, and urea/BUN values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and FU |
|-----------------|---|

End point description:

Potassium, glucose, calcium, cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, chloride, creatinine, sodium, triglycerides, and urea/BUN values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[19] | 13 ^[20] | 12 ^[21] | |
| Units: Millimoles/liter (mmol/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Potassium, Screening, n=12, 13, 12 | 4.41 (± 0.494) | 4.32 (± 0.377) | 4.37 (± 0.41) | |
| Potassium, Day 1: pre-dose, n=12, 12, 12 | 4.3 (± 0.349) | 4.27 (± 0.331) | 4.28 (± 0.351) | |
| Potassium, Day 1: 4 hr, n= 11, 12, 11 | 4 (± 0.654) | 4.18 (± 0.374) | 4.42 (± 0.506) | |
| Potassium, Day 4, n=11, 13, 11 | 4.35 (± 0.281) | 4.42 (± 0.637) | 4.46 (± 0.266) | |
| Potassium, Day 9, n=12, 13, 12 | 4.37 (± 0.308) | 4.28 (± 0.359) | 4.54 (± 0.37) | |
| Potassium, Day 14, n=12, 13, 12 | 4.51 (± 0.468) | 4.5 (± 0.497) | 4.66 (± 0.613) | |
| Potassium, Day 21, n=12, 13, 12 | 4.42 (± 0.371) | 4.51 (± 0.388) | 4.56 (± 0.466) | |
| Potassium, Day 29: pre-dose, n=11, 13, 12 | 4.27 (± 0.561) | 4.19 (± 0.366) | 4.3 (± 0.388) | |
| Potassium, Day 29: 4 hr, n=12, 10, 11 | 4.32 (± 0.6) | 4 (± 0.478) | 4.25 (± 0.468) | |
| Potassium, Day 32, n=11, 13, 12 | 4.48 (± 0.343) | 4.59 (± 0.689) | 4.51 (± 0.442) | |
| Potassium, Day 42, n=12, 13, 12 | 4.51 (± 0.219) | 4.48 (± 0.511) | 4.66 (± 0.558) | |
| Potassium, Day 57, n=12, 13, 12 | 4.48 (± 0.515) | 4.28 (± 0.277) | 4.25 (± 0.355) | |
| Potassium, Day 85, n=11, 12, 12 | 4.37 (± 0.358) | 4.4 (± 0.451) | 4.38 (± 0.51) | |
| Potassium, Day 120, n=11, 13, 12 | 4.51 (± 0.308) | 4.56 (± 0.686) | 4.4 (± 0.437) | |
| Potassium, Day 165, n=12, 12, 11 | 4.52 (± 0.609) | 4.38 (± 0.411) | 4.19 (± 0.532) | |
| Potassium, follow-up, n=12, 12, 12 | 4.5 (± 0.499) | 4.42 (± 0.465) | 4.52 (± 0.371) | |
| Glucose, Day 1: pre-dose, n=12, 13, 12 | 10.04 (± 2.545) | 8.64 (± 1.532) | 9.26 (± 1.89) | |
| Glucose, Day 1: 4 hr, n= 12, 13, 12 | 12.45 (± 4.058) | 9.33 (± 1.7) | 11.65 (± 3.087) | |
| Glucose, Day 4, n=11, 13, 11 | 9.91 (± 2.117) | 8.41 (± 1.317) | 9.33 (± 1.939) | |
| Glucose, Day 9, n=12, 13, 12 | 9.72 (± 1.799) | 8.32 (± 1.445) | 9.08 (± 1.173) | |
| Glucose, Day 14, n=11, 13, 12 | 9.76 (± 1.691) | 8.7 (± 1.942) | 8.88 (± 1.633) | |
| Glucose, Day 21, n=12, 13, 12 | 9.77 (± 1.308) | 8.86 (± 2.042) | 9.08 (± 1.904) | |
| Glucose, Day 29: pre-dose, n=12, 13, 12 | 9.76 (± 1.898) | 8.37 (± 1.758) | 9.22 (± 1.736) | |
| Glucose, Day 29: 4 hr, n=12, 13, 12 | 11.55 (± 3.987) | 10.01 (± 2.761) | 10.73 (± 2.776) | |
| Glucose, Day 32, n=12, 13, 12 | 9.58 (± 1.436) | 8.64 (± 1.877) | 9.15 (± 1.868) | |

| | | | | |
|---|------------------|------------------|------------------|--|
| Glucose, Day 42, n=12, 13, 12 | 9.84 (± 1.829) | 8.22 (± 1.438) | 9.68 (± 3.568) | |
| Glucose, Day 57, n=12, 13, 12 | 9.05 (± 1.652) | 8.43 (± 1.849) | 8.13 (± 1.659) | |
| Glucose, Day 85, n=12, 13, 12 | 9.25 (± 1.71) | 8.82 (± 2.127) | 8.68 (± 2.146) | |
| Glucose, Day 120, n=11, 13, 12 | 8.73 (± 1.716) | 9.62 (± 2.533) | 9.01 (± 1.714) | |
| Glucose, Day 165, n=12, 13, 12 | 8.84 (± 1.388) | 8.98 (± 2.318) | 8.94 (± 1.713) | |
| Glucose, follow-up, n=12, 13, 12 | 9.81 (± 2.475) | 8.67 (± 2.322) | 9.55 (± 3.499) | |
| Calcium, Screening, n=12, 13, 12 | 2.467 (± 0.0931) | 2.445 (± 0.0723) | 2.416 (± 0.0742) | |
| Calcium, Day 1: pre-dose, n=12, 12, 12 | 2.35 (± 0.1681) | 2.361 (± 0.1423) | 2.405 (± 0.0888) | |
| Calcium, Day 1: 4 hr, n= 11, 12, 11 | 2.322 (± 0.2997) | 2.4 (± 0.1135) | 2.401 (± 0.1018) | |
| Calcium, Day 4, n=11, 13, 11 | 2.45 (± 0.0647) | 2.382 (± 0.0941) | 2.424 (± 0.1083) | |
| Calcium, Day 9, n=12, 13, 12 | 2.473 (± 0.0913) | 2.406 (± 0.0749) | 2.428 (± 0.1194) | |
| Calcium, Day 14, n=12, 13, 12 | 2.465 (± 0.0657) | 2.396 (± 0.0947) | 2.341 (± 0.1847) | |
| Calcium, Day 21, n=12, 13, 12 | 2.453 (± 0.0729) | 2.423 (± 0.0774) | 2.377 (± 0.0986) | |
| Calcium, Day 29: pre-dose, n=11, 13, 12 | 2.394 (± 0.2223) | 2.335 (± 0.1815) | 2.392 (± 0.079) | |
| Calcium, Day 29: 4 hr, n=12, 10, 11 | 2.351 (± 0.2092) | 2.301 (± 0.2548) | 2.355 (± 0.1026) | |
| Calcium, Day 32, n=11, 13, 12 | 2.425 (± 0.0505) | 2.392 (± 0.1129) | 2.399 (± 0.0762) | |
| Calcium, Day 42, n=12, 13, 12 | 2.456 (± 0.0784) | 2.404 (± 0.0636) | 2.397 (± 0.1367) | |
| Calcium, Day 57, n=12, 13, 12 | 2.411 (± 0.1108) | 2.319 (± 0.1689) | 2.383 (± 0.1041) | |
| Calcium, Day 85, n=11, 12, 12 | 2.455 (± 0.0792) | 2.413 (± 0.1013) | 2.423 (± 0.1314) | |
| Calcium, Day 120, n=11, 13, 12 | 2.448 (± 0.1002) | 2.365 (± 0.1761) | 2.407 (± 0.0579) | |
| Calcium, Day 165, n=12, 12, 11 | 2.459 (± 0.1145) | 2.426 (± 0.0915) | 2.396 (± 0.1068) | |
| Calcium, follow-up, n=12, 11, 12 | 2.453 (± 0.0758) | 2.37 (± 0.0952) | 2.412 (± 0.0992) | |
| Cholesterol, Screening, n=12, 13, 12 | 4.691 (± 0.9451) | 4.616 (± 0.9833) | 4.93 (± 1.135) | |
| Cholesterol, Day 1: pre-dose, n= 12, 12 | 4.445 (± 0.7338) | 4.442 (± 1.0774) | 4.501 (± 1.2156) | |
| Cholesterol, Day 1: 4 hr, n=11, 12, 11 | 4.189 (± 0.8437) | 4.361 (± 0.7929) | 4.307 (± 1.2554) | |
| Cholesterol, Day 4, n=11, 13, 11 | 4.489 (± 0.7969) | 4.465 (± 0.9046) | 4.38 (± 1.2766) | |
| Cholesterol, Day 9, n=12, 13, 12 | 4.454 (± 0.8224) | 4.365 (± 0.8639) | 4.325 (± 1.1791) | |
| Cholesterol, Day 14, n=12, 13, 12 | 4.428 (± 0.9009) | 4.37 (± 0.875) | 4.4 (± 1.1531) | |
| Cholesterol, Day 21, n=12, 13, 12 | 4.434 (± 0.9178) | 4.528 (± 0.8273) | 4.452 (± 1.2251) | |
| Cholesterol, Day 29: pre-dose, n=11, 13, 12 | 4.221 (± 0.8373) | 4.281 (± 1.0434) | 4.562 (± 1.0764) | |
| Cholesterol, Day 29: 4 hr, n=12, 10, 11 | 4.236 (± 0.9041) | 4.009 (± 0.8938) | 4.265 (± 1.1512) | |
| Cholesterol, Day 32, n=11, 13, 12 | 4.542 (± 0.8357) | 4.305 (± 0.8342) | 4.462 (± 1.0283) | |
| Cholesterol, Day 42, n=12, 13, 12 | 4.698 (± 0.6961) | 4.312 (± 0.7405) | 4.531 (± 1.1809) | |

| | | | | |
|--------------------------------------|------------------|------------------|------------------|--|
| Cholesterol, Day 57, n=12, 13, 12 | 4.785 (± 1.0829) | 4.292 (± 0.829) | 4.763 (± 1.5079) | |
| Cholesterol, Day 85, n=11, 12, 12 | 4.936 (± 1.2475) | 4.582 (± 0.9766) | 4.585 (± 1.2112) | |
| Cholesterol, Day 120, n=11, 13, 12 | 4.56 (± 0.9324) | 4.364 (± 1.0527) | 4.778 (± 1.2748) | |
| Cholesterol, Day 165, n=12, 12, 12 | 4.691 (± 1.0977) | 4.345 (± 0.7629) | 4.748 (± 1.0543) | |
| Cholesterol, follow-up, n=12, 12, 12 | 4.944 (± 1.1249) | 4.64 (± 0.8404) | 4.32 (± 1.2699) | |
| HCD, Screening, n=12, 13, 12 | 1.038 (± 0.2031) | 1.068 (± 0.2076) | 1.103 (± 0.3764) | |
| HCD, Day 1: pre-dose, n=12, 12, 12 | 0.987 (± 0.1997) | 1.021 (± 0.1821) | 1.028 (± 0.3983) | |
| HCD, Day 1: 4 hr, n= 11, 12, 11 | 0.882 (± 0.2371) | 0.905 (± 0.1766) | 0.908 (± 0.3601) | |
| HCD, Day 4, n=11, 13, 11 | 1.016 (± 0.1767) | 1.018 (± 0.1763) | 1.059 (± 0.4174) | |
| HCD, Day 9, n=12, 13, 12 | 1.044 (± 0.2095) | 1.052 (± 0.2055) | 1.092 (± 0.4131) | |
| HCD, Day 14, n=12, 13, 12 | 1.031 (± 0.2288) | 1.058 (± 0.231) | 1.128 (± 0.4724) | |
| HCD, Day 21, n=12, 13, 12 | 1.059 (± 0.2206) | 1.086 (± 0.2239) | 1.15 (± 0.5763) | |
| HCD, Day 29: pre-dose, n=11, 13,12 | 0.979 (± 0.2402) | 1.035 (± 0.1966) | 1.144 (± 0.5198) | |
| HCD, Day 29: 4 hr, n=12, 10, 11 | 0.89 (± 0.1842) | 0.945 (± 0.2067) | 1.035 (± 0.5248) | |
| HCD, Day 32, n=11, 13, 12 | 1.056 (± 0.2792) | 1.049 (± 0.2238) | 1.128 (± 0.4264) | |
| HCD, Day 42, n=12, 13, 12 | 1.05 (± 0.2429) | 1.061 (± 0.2222) | 1.147 (± 0.4933) | |
| HCD, Day 57, n=12, 13, 12 | 1.008 (± 0.2057) | 1.066 (± 0.2412) | 1.143 (± 0.4881) | |
| HCD, Day 85, n=11, 12, 12 | 1.034 (± 0.2695) | 1.071 (± 0.2734) | 1.147 (± 0.4588) | |
| HCD, Day 120, n=11, 13, 12 | 1.043 (± 0.2749) | 1.111 (± 0.3225) | 1.143 (± 0.4692) | |
| HCD, Day 165, n=12, 12, 12 | 1.04 (± 0.2663) | 1.123 (± 0.2947) | 1.115 (± 0.3964) | |
| HCD, follow-up, n=12, 12, 12 | 1.118 (± 0.2713) | 1.103 (± 0.2074) | 1.101 (± 0.4437) | |
| LCC, Screening, n=12, 13, 12 | 2.554 (± 0.808) | 2.669 (± 0.8961) | 2.937 (± 1.131) | |
| LCC, Day 1: pre-dose, n=12, 12, 12 | 2.361 (± 0.8784) | 2.624 (± 0.9658) | 2.564 (± 1.1659) | |
| LCC, Day 1: 4 hr, n=11, 12, 10 | 1.907 (± 0.7812) | 2.228 (± 0.7441) | 2.228 (± 1.1966) | |
| LCC, Day 4, n=11, 13, 11 | 2.373 (± 0.8578) | 2.684 (± 0.8231) | 2.605 (± 1.2231) | |
| LCC, Day 9, n=12, 13, 12 | 2.304 (± 0.7187) | 2.523 (± 0.8824) | 2.449 (± 1.1501) | |
| LCC, Day 14, n=12, 13, 12 | 2.273 (± 0.7569) | 2.497 (± 0.7612) | 2.484 (± 1.0383) | |
| LCC, Day 21, n=12, 13, 12 | 2.346 (± 0.9068) | 2.577 (± 0.8484) | 2.468 (± 0.9989) | |
| LCC, Day 29: pre-dose, n=11, 13, 12 | 2.185 (± 0.8694) | 2.522 (± 1.0284) | 2.521 (± 0.9772) | |
| LCC, Day 29: 4 hr, n=12, 10, 11 | 1.998 (± 0.8793) | 2.067 (± 0.8523) | 2.105 (± 1.0604) | |
| LCC, Day 32, n=11, 13, 12 | 2.482 (± 0.6992) | 2.45 (± 0.7498) | 2.583 (± 0.9974) | |

| | | | | |
|---|------------------|------------------|------------------|--|
| LCC, Day 42, n=11, 13, 12 | 2.693 (± 0.6449) | 2.505 (± 0.7698) | 2.563 (± 1.0248) | |
| LCC, Day 57, n=12, 13, 12 | 2.587 (± 1.0039) | 2.474 (± 0.8736) | 2.693 (± 1.3943) | |
| LCC, Day 85, n=11, 12, 12 | 2.738 (± 1.1679) | 2.598 (± 0.885) | 2.587 (± 1.1567) | |
| LCC, Day 120, n=10, 13, 12 | 2.591 (± 0.8264) | 2.435 (± 0.9239) | 2.639 (± 1.138) | |
| LCC, Day 165, n=12, 12, 12 | 2.556 (± 1.2146) | 2.453 (± 0.6825) | 2.718 (± 1.119) | |
| LCC, follow-up, n=12, 12, 12 | 2.672 (± 1.224) | 2.736 (± 0.7792) | 2.366 (± 1.2395) | |
| Chloride, Screening, n=12, 13, 12 | 103.6 (± 2.39) | 101.7 (± 2.98) | 103.1 (± 3.45) | |
| Chloride, Day 1: pre-dose, n=12, 12, 12 | 104.2 (± 2.92) | 103.2 (± 3.71) | 103.2 (± 3.59) | |
| Chloride, Day 1: 4 hr, n= 11, 12, 11 | 103.3 (± 5.14) | 101.8 (± 3.16) | 102.7 (± 3.38) | |
| Chloride, Day 4, n=11, 13, 11 | 102.3 (± 3.13) | 102.1 (± 2.5) | 103.9 (± 4.44) | |
| Chloride, Day 9, n=12, 13, 12 | 102.8 (± 1.82) | 102 (± 2.24) | 103.9 (± 3.15) | |
| Chloride, Day 14, n=12, 13, 12 | 102.1 (± 2.5) | 102.8 (± 3.05) | 103.7 (± 4.23) | |
| Chloride, Day 21, n=12, 13, 12 | 103.2 (± 2.59) | 102.2 (± 3.48) | 104 (± 2.76) | |
| Chloride, Day 29: pre-dose, n=11, 13, 12 | 104.5 (± 3.21) | 103.2 (± 1.86) | 103.2 (± 3.24) | |
| Chloride, Day 29: 4 hr, n=12, 10, 11 | 102.6 (± 4.21) | 103.2 (± 5.12) | 103.9 (± 2.84) | |
| Chloride, Day 32, n=11, 13, 12 | 103.5 (± 3.24) | 102.4 (± 2.53) | 103.7 (± 3.45) | |
| Chloride, Day 42, n=12, 13, 12 | 102.8 (± 2.34) | 102.7 (± 2.98) | 102.8 (± 2.59) | |
| Chloride, Day 57, n=12, 13, 12 | 103.4 (± 1.83) | 104.1 (± 3.95) | 104.1 (± 3) | |
| Chloride, Day 85, n=11, 12, 12 | 103.5 (± 2.88) | 102.7 (± 2.57) | 103.8 (± 3.44) | |
| Chloride, Day 120, n=11, 13, 12 | 102.8 (± 1.94) | 102.5 (± 2.88) | 103 (± 3.19) | |
| Chloride, Day 165, n=12, 12, 12 | 103.3 (± 2.34) | 103.1 (± 2.94) | 102.7 (± 3.65) | |
| Chloride, follow-up, n=12, 12, 12 | 103.3 (± 2.53) | 102.1 (± 2.91) | 103.4 (± 3.37) | |
| Sodium, Screening, n=12, 13, 12 | 140.3 (± 1.96) | 138.5 (± 2.15) | 138.8 (± 1.19) | |
| Sodium, Day 1: pre-dose, n=12, 12, 12 | 139.4 (± 2.15) | 138.5 (± 3.03) | 139.2 (± 1.47) | |
| Sodium, Day 1: 4 hr, n=11, 12, 11 | 138 (± 2.83) | 138.3 (± 2.38) | 137.7 (± 1.9) | |
| Sodium, Day 4, n=11, 13, 11 | 138.9 (± 2.07) | 139.3 (± 2.36) | 139.2 (± 1.89) | |
| Sodium, Day 9, n=12, 13, 12 | 138.8 (± 2.04) | 138 (± 1.78) | 139.3 (± 1.54) | |
| Sodium, Day 14, n=12, 13, 12 | 139.5 (± 1.17) | 139.6 (± 2.43) | 139.9 (± 2.19) | |
| Sodium, Day 21, n=12, 13, 12 | 139.3 (± 1.61) | 138.5 (± 2.37) | 139.7 (± 1.56) | |
| Sodium, Day 29: pre-dose, n=11, 13, 12 | 139.5 (± 1.69) | 138.5 (± 1.9) | 139.2 (± 2.29) | |
| Sodium, Day 29: 4 hr, n=12, 10, 11 | 137.9 (± 2.87) | 139.2 (± 3.08) | 138.1 (± 1.58) | |
| Sodium, Day 32, n=11, 13, 12 | 139.6 (± 1.69) | 139.5 (± 2.07) | 139 (± 1.71) | |
| Sodium, Day 42, n=12, 13, 12 | 139.2 (± 2.29) | 139.2 (± 1.77) | 138.5 (± 1.78) | |
| Sodium, Day 57, n=12, 13, 12 | 140.1 (± 1.73) | 138.5 (± 2.54) | 140.1 (± 1.98) | |
| Sodium, Day 85, n=11, 12, 12 | 139.1 (± 2.21) | 138.5 (± 1.45) | 139.4 (± 1.38) | |
| Sodium, Day 120, n=11, 13, 12 | 139.4 (± 2.2) | 138.7 (± 3.2) | 139.6 (± 1.38) | |
| Sodium, Day 165, n=12, 12, 12 | 139.3 (± 1.48) | 138.6 (± 2.61) | 138.4 (± 1.38) | |
| Sodium, follow-up, n=12, 12, 12 | 139.7 (± 1.97) | 139.1 (± 2.39) | 139.5 (± 2.68) | |
| Triglyceride, Screening, n=12, 13, 12 | 2.398 (± 0.9159) | 1.915 (± 0.8348) | 1.941 (± 0.6399) | |
| Triglyceride, Day 1: pre-dose, n=12, 12, 12 | 2.394 (± 0.802) | 1.736 (± 0.8439) | 1.988 (± 0.7275) | |
| Triglyceride, Day 1: 4 hr, n=11, 12, 11 | 3.055 (± 0.6153) | 2.676 (± 0.9959) | 2.575 (± 1.0535) | |
| Triglyceride, Day 4, n=11, 13, 11 | 2.396 (± 1.1058) | 1.663 (± 0.6341) | 1.554 (± 0.4501) | |
| Triglyceride, Day 9, n=12, 13, 12 | 2.41 (± 0.7973) | 1.722 (± 0.8948) | 1.707 (± 0.8005) | |

| | | | |
|--|------------------|------------------|------------------|
| Triglyceride, Day 14, n=12, 13, 12 | 2.448 (± 0.8671) | 1.774 (± 0.8668) | 1.718 (± 0.6216) |
| Triglyceride, Day 21, n=12, 13, 12 | 2.243 (± 0.739) | 1.887 (± 0.8812) | 1.818 (± 0.8204) |
| Triglyceride, Day 29: pre-dose, n=11, 13, 12 | 2.305 (± 0.785) | 1.582 (± 0.7214) | 1.953 (± 0.733) |
| Triglyceride, Day 29: 4 hr, n=12, 10, 11 | 2.941 (± 0.5848) | 2.172 (± 1.0823) | 2.454 (± 0.8392) |
| Triglyceride, Day 32, n=11, 13, 12 | 2.186 (± 0.8153) | 1.755 (± 0.8522) | 1.64 (± 0.4573) |
| Triglyceride, Day 42, n=12, 13, 12 | 2.598 (± 1.5567) | 1.625 (± 0.5765) | 1.787 (± 0.5062) |
| Triglyceride, Day 57, n=12, 13, 12 | 2.597 (± 0.8576) | 1.642 (± 0.687) | 2.019 (± 0.7403) |
| Triglyceride, Day 85, n=11, 12, 12 | 2.54 (± 0.8901) | 1.987 (± 0.6512) | 1.856 (± 0.5816) |
| Triglyceride, Day 120, n=11, 13, 12 | 2.522 (± 1.4038) | 1.785 (± 1.012) | 2.174 (± 0.6871) |
| Triglyceride, Day 165, n=12, 12, 12 | 2.387 (± 1.0518) | 1.675 (± 0.866) | 1.998 (± 0.7234) |
| Triglyceride, follow-up, n=12, 12, 12 | 2.516 (± 1.0983) | 1.748 (± 0.7628) | 1.858 (± 0.6771) |
| Urea/BUN, Screening, n=12, 13, 12 | 7.56 (± 2.65) | 5.52 (± 1.357) | 6.15 (± 2.388) |
| Urea/BUN, Day 1: pre-dose, n=12, 12, 12 | 6.33 (± 1.866) | 5.53 (± 1.281) | 6.76 (± 4.384) |
| Urea/BUN, Day 1: 4 hr, n=11, 12, 11 | 6.3 (± 1.581) | 6.01 (± 1.178) | 7.32 (± 4.064) |
| Urea/BUN, Day 4, n=11, 13, 11 | 6.76 (± 1.397) | 5.75 (± 0.759) | 6.58 (± 2.923) |
| Urea/BUN, Day 9, n=12, 13, 12 | 6.41 (± 1.005) | 5.35 (± 1.087) | 6.98 (± 3.595) |
| Urea/BUN, Day 14, n=12, 13, 12 | 6.48 (± 1.434) | 5.99 (± 1.495) | 6.7 (± 3.821) |
| Urea/BUN, Day 21, n=12, 13, 12 | 6.86 (± 1.685) | 5.75 (± 1.222) | 6.36 (± 1.846) |
| Urea/BUN, Day 29: pre-dose, n=11, 13, 12 | 6.97 (± 2.039) | 5.54 (± 1.309) | 5.85 (± 1.633) |
| Urea/BUN, Day 29: 4 hr, n=12, 10, 11 | 7.13 (± 1.697) | 5.73 (± 0.906) | 6.55 (± 1.929) |
| Urea/BUN, Day 32, n=11, 13, 12 | 6.86 (± 1.604) | 5.78 (± 1.118) | 6.38 (± 2.173) |
| Urea/BUN, Day 42, n=12, 13, 12 | 6.53 (± 1.224) | 5.67 (± 1.005) | 6.4 (± 1.744) |
| Urea/BUN, Day 57, n=12, 13, 12 | 6.68 (± 1.805) | 5.65 (± 1.335) | 6.27 (± 2.163) |
| Urea/BUN, Day 85, n=11, 12, 12 | 6.72 (± 1.211) | 5.76 (± 1.835) | 6.33 (± 2.106) |
| Urea/BUN, Day 120, n=11, 13, 12 | 7.46 (± 1.751) | 5.92 (± 1.101) | 6.19 (± 1.771) |
| Urea/BUN, Day 165, n=12, 12, 12 | 6.93 (± 2.355) | 6.03 (± 1.463) | 6.25 (± 2.058) |
| Urea/BUN, follow-up, n=12, 12, 12 | 7.04 (± 1.929) | 6.03 (± 1.069) | 6.38 (± 2.086) |

Notes:

[19] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[20] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[21] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Total cholesterol/HDL ratio (TC/HDL ratio), HDL/LDL ratio, and triglyceride/HDL ratio (TG/HDL ratio) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Total cholesterol/HDL ratio (TC/HDL ratio), HDL/LDL ratio, and triglyceride/HDL ratio (TG/HDL ratio) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

TC/HDL ratio, HDL/LDL ratio, and triglyceride/HDL ratio values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|-----------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[22] | 13 ^[23] | 12 ^[24] | |
| Units: Ratio | | | | |
| arithmetic mean (standard deviation) | | | | |
| TC/HDL ratio, Screening, n=12, 13, 12 | 4.5517 (± 0.67139) | 4.4335 (± 1.16277) | 4.8275 (± 1.61827) | |
| TC/HDL ratio, Day 1: pre-dose, n=12, 12, 12 | 4.5833 (± 0.75575) | 4.4437 (± 1.3486) | 4.8528 (± 1.98221) | |
| TC/HDL ratio, Day 1: 4 hr, n= 11, 12, 11 | 4.8928 (± 0.95411) | 4.9908 (± 1.40456) | 5.2906 (± 2.31631) | |
| TC/HDL ratio, Day 4, n=11, 13, 11 | 4.4785 (± 0.79579) | 4.4726 (± 1.16211) | 4.539 (± 1.81475) | |
| TC/HDL ratio, Day 9, n=12, 13, 12 | 4.3908 (± 1.05287) | 4.2825 (± 1.21595) | 4.3225 (± 1.66246) | |
| TC/HDL ratio, Day 14, n=12, 13, 12 | 4.3954 (± 0.93858) | 4.266 (± 1.16649) | 4.2618 (± 1.56118) | |
| TC/HDL ratio, Day 21, n=12, 13, 12 | 4.264 (± 0.81159) | 4.3206 (± 1.22274) | 4.3941 (± 1.90723) | |
| TC/HDL ratio, Day 29: pre-dose, n=11, 13, 12 | 4.3882 (± 0.73541) | 4.2708 (± 1.36303) | 4.544 (± 2.02278) | |
| TC/HDL ratio, Day 29: 4 hr, n=12, 10, 11 | 4.8172 (± 0.92837) | 4.4191 (± 1.45277) | 4.7201 (± 2.12839) | |
| TC/HDL ratio, Day 32, n=11, 13, 12 | 4.4461 (± 0.87461) | 4.3118 (± 1.51533) | 4.323 (± 1.6147) | |
| TC/HDL ratio, Day 42, n=12, 13, 12 | 4.6364 (± 1.06085) | 4.2224 (± 1.14198) | 4.3167 (± 1.59367) | |
| TC/HDL ratio, Day 57, n=12, 13, 12 | 4.8836 (± 1.42324) | 4.221 (± 1.29056) | 4.5542 (± 1.97068) | |
| TC/HDL ratio, Day 85, n=11, 12, 12 | 4.97 (± 1.58565) | 4.5079 (± 1.43704) | 4.421 (± 1.9158) | |
| TC/HDL ratio, Day 120, n=11, 13, 12 | 4.4824 (± 0.67007) | 4.2153 (± 1.71395) | 4.6894 (± 2.096) | |
| TC/HDL ratio, Day 165, n=12, 12, 12 | 4.6683 (± 1.2241) | 4.1097 (± 1.38627) | 4.7094 (± 1.87947) | |
| TC/HDL ratio, follow-up, n=12, 12, 12 | 4.5717 (± 1.11481) | 4.3414 (± 1.13258) | 4.258 (± 1.43006) | |
| HDL/LDL ratio, Screening, n=12, 13, 12 | 0.4322 (± 0.11034) | 0.4349 (± 0.14208) | 0.4299 (± 0.21361) | |
| HDL/LDL ratio, Day 1: pre-dose, n=12, 12, 12 | 0.489 (± 0.2366) | 0.4271 (± 0.13) | 0.4816 (± 0.28547) | |
| HDL/LDL ratio, Day 1: 4 hr, n=11, 12, 10 | 0.571 (± 0.31912) | 0.4393 (± 0.12977) | 0.5166 (± 0.29093) | |
| HDL/LDL ratio, Day 4, n=11, 13, 11 | 0.4904 (± 0.2106) | 0.409 (± 0.12033) | 0.4879 (± 0.27487) | |
| HDL/LDL ratio, Day 9, n=12, 13, 12 | 0.4962 (± 0.1882) | 0.4571 (± 0.15287) | 0.5602 (± 0.33874) | |

| | | | | |
|---|--------------------|--------------------|--------------------|--|
| HDL/LDL ratio, Day 14, n=12, 13, 12 | 0.4958 (± 0.18073) | 0.4536 (± 0.13598) | 0.5247 (± 0.2519) | |
| HDL/LDL ratio, Day 21, n=12, 13, 12 | 0.5028 (± 0.17479) | 0.4568 (± 0.14559) | 0.5263 (± 0.2703) | |
| HDL/LDL ratio, Day 29: pre-dose, n=11, 13, 12 | 0.5429 (± 0.29396) | 0.4583 (± 0.15254) | 0.5254 (± 0.32512) | |
| HDL/LDL ratio, Day 29: 4 hr, n=11, 10, 11 | 0.569 (± 0.33723) | 0.511 (± 0.17463) | 0.5969 (± 0.32829) | |
| HDL/LDL ratio, Day 32, n=11, 13, 12 | 0.4463 (± 0.12702) | 0.4682 (± 0.16788) | 0.5001 (± 0.25773) | |
| HDL/LDL ratio, Day 42, n=11, 13, 12 | 0.4219 (± 0.14536) | 0.4587 (± 0.15812) | 0.5164 (± 0.25657) | |
| HDL/LDL ratio, Day 57, n=12, 13, 12 | 0.4418 (± 0.17798) | 0.4759 (± 0.18751) | 0.5732 (± 0.41531) | |
| HDL/LDL ratio, Day 85, n=11, 12, 12 | 0.4347 (± 0.17966) | 0.4483 (± 0.16274) | 0.5525 (± 0.38936) | |
| HDL/LDL ratio, Day 120, n=10, 13, 12 | 0.4365 (± 0.10934) | 0.4966 (± 0.17561) | 0.5176 (± 0.3155) | |
| HDL/LDL ratio, Day 165, n=12, 12, 12 | 0.5048 (± 0.27435) | 0.4811 (± 0.15581) | 0.5289 (± 0.44948) | |
| HDL/LDL ratio, follow-up, n=12, 12, 12 | 0.4963 (± 0.2287) | 0.4322 (± 0.14335) | 0.581 (± 0.37442) | |
| TG/HDL ratio, Screening, n=12, 13, 12 | 2.3782 (± 0.97356) | 1.9368 (± 1.10017) | 2.0276 (± 1.1114) | |
| TG/HDL ratio, Day 1: pre-dose, n=12, 12, 12 | 2.5398 (± 1.09229) | 1.7328 (± 0.81922) | 2.2982 (± 1.40144) | |
| TG/HDL ratio, Day 1: 4 hr, n=11, 12, 11 | 3.7321 (± 1.34144) | 3.1181 (± 1.41296) | 3.3154 (± 1.89189) | |
| TG/HDL ratio, Day 4, n=11, 13, 11 | 2.5015 (± 1.33091) | 1.6556 (± 0.59018) | 1.7557 (± 1.0279) | |
| TG/HDL ratio, Day 9, n=12, 13, 12 | 2.4587 (± 1.08718) | 1.7316 (± 0.94072) | 1.8978 (± 1.26276) | |
| TG/HDL ratio, Day 14, n=12, 13, 12 | 2.5216 (± 1.13514) | 1.8014 (± 1.0782) | 1.8224 (± 1.15332) | |
| TG/HDL ratio, Day 21, n=12, 13, 12 | 2.2854 (± 1.11024) | 1.9121 (± 1.22395) | 1.965 (± 1.25287) | |
| TG/HDL ratio, Day 29: pre-dose, n=11, 13, 12 | 2.5333 (± 1.26093) | 1.6627 (± 1.04388) | 2.1053 (± 1.38927) | |
| TG/HDL ratio, Day 29: 4 hr, n=12, 10, 11 | 3.4249 (± 1.02583) | 2.4966 (± 1.45071) | 2.8369 (± 1.54468) | |
| TG/HDL ratio, Day 32, n=11, 13, 12 | 2.2721 (± 1.07761) | 1.8371 (± 1.25628) | 1.6781 (± 0.79591) | |
| TG/HDL ratio, Day 42, n=12, 13, 12 | 2.7965 (± 2.27015) | 1.6805 (± 0.89388) | 1.8026 (± 0.87202) | |
| TG/HDL ratio, Day 57, n=12, 13, 12 | 2.7234 (± 1.12785) | 1.7039 (± 1.04513) | 1.9699 (± 0.99277) | |
| TG/HDL ratio, Day 85, n=11, 12, 12 | 2.7858 (± 1.62412) | 2.0578 (± 1.04219) | 1.827 (± 0.91655) | |
| TG/HDL ratio, Day 120, n=11, 13, 12 | 2.781 (± 2.29533) | 1.9532 (± 1.78872) | 2.2421 (± 1.27475) | |
| TG/HDL ratio, Day 165, n=12, 12, 12 | 2.5915 (± 1.63262) | 1.7162 (± 1.37165) | 2.0827 (± 1.22584) | |
| TG/HDL ratio, follow-up, n=12, 12, 12 | 2.512 (± 1.49353) | 1.675 (± 0.83953) | 1.9843 (± 1.18512) | |

Notes:

[22] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[23] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[24] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

Secondary: Glomerular filtration rate (GFR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Glomerular filtration rate (GFR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

GFR values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|----------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[25] | 13 ^[26] | 12 ^[27] | |
| Units: mL/second/1.73 meters squared (m ²) | | | | |
| arithmetic mean (standard deviation) | | | | |
| GFR, Day 1: pre-dose, n=12, 12, 12 | 1.58511 (± 0.277574) | 2.02627 (± 0.46816) | 1.67696 (± 0.608263) | |
| GFR, Day 1: 4 hr, n= 11, 11, 11 | 1.59561 (± 0.4595) | 1.63205 (± 0.416637) | 1.40432 (± 0.491131) | |
| GFR, Day 4, n=11, 13, 11 | 1.41343 (± 0.288603) | 1.78818 (± 0.405897) | 1.63053 (± 0.503625) | |
| GFR, Day 9, n=12, 13, 12 | 1.44594 (± 0.226133) | 1.79975 (± 0.455115) | 1.54058 (± 0.531265) | |
| GFR, Day 14, n=12, 13, 12 | 1.44316 (± 0.21988) | 1.71753 (± 0.436966) | 1.60877 (± 0.538198) | |
| GFR, Day 21, n=12, 13, 12 | 1.44316 (± 0.226469) | 1.75093 (± 0.429564) | 1.54893 (± 0.430925) | |
| GFR, Day 29: pre-dose, n=11, 13, 12 | 1.54551 (± 0.347694) | 1.90508 (± 0.475019) | 1.66443 (± 0.455756) | |
| GFR, Day 29: 4 hr, n=12, 9, 11 | 1.4195 (± 0.295839) | 1.66258 (± 0.314443) | 1.37395 (± 0.359659) | |
| GFR, Day 32, n=11, 13, 12 | 1.46353 (± 0.280965) | 1.65844 (± 0.379313) | 1.62547 (± 0.509746) | |
| GFR, Day 42, n=12, 13, 12 | 1.42646 (± 0.227363) | 1.71239 (± 0.37693) | 1.5197 (± 0.443158) | |
| GFR, Day 57, n=12, 13, 12 | 1.44316 (± 0.280753) | 1.89481 (± 0.491664) | 1.63799 (± 0.479404) | |
| GFR, Day 85, n=12, 12, 12 | 1.45568 (± 0.227182) | 1.78551 (± 0.428052) | 1.59068 (± 0.427914) | |
| GFR, Day 120, n=11, 13, 12 | 1.36636 (± 0.231621) | 1.70725 (± 0.44379) | 1.48491 (± 0.390837) | |
| GFR, Day 165, n=12, 12, 12 | 1.34157 (± 0.158323) | 1.77855 (± 0.601052) | 1.52527 (± 0.417065) | |
| GFR, follow-up, n=12, 12, 12 | 1.35966 (± 0.219071) | 1.71036 (± 0.533234) | 1.46821 (± 0.4867) | |

Notes:

[25] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[26] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[27] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil (SN), TN, platelet count, and WBC count values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil (SN), TN, platelet count, and WBC count values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

Basophil, eosinophil, lymphocyte, monocyte, SN, total neutrophil (TN), platelet count, and white blood cell (WBC) count values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[28] | 13 ^[29] | 12 ^[30] | |
| Units: 10 ⁹ cells per liter (GI/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Basophils, Screening, n=12, 12, 11 | 0.035 (± 0.0109) | 0.026 (± 0.0156) | 0.024 (± 0.0121) | |
| Basophils, Day 1: pre-dose, n=12, 13, 11 | 0.031 (± 0.009) | 0.028 (± 0.0109) | 0.026 (± 0.0175) | |
| Basophils, Day 1: 4 hr, n=12, 12, 11 | 0.027 (± 0.0115) | 0.027 (± 0.0115) | 0.028 (± 0.0154) | |
| Basophils, Day 4, n=11, 12, 11 | 0.037 (± 0.0149) | 0.038 (± 0.0269) | 0.032 (± 0.0125) | |
| Basophils, Day 9, n=12, 13, 12 | 0.029 (± 0.0067) | 0.028 (± 0.0121) | 0.035 (± 0.0183) | |
| Basophils, Day 14, n=12, 12, 12 | 0.039 (± 0.0116) | 0.035 (± 0.0157) | 0.032 (± 0.014) | |
| Basophils, Day 21, n=12, 13, 12 | 0.036 (± 0.0151) | 0.032 (± 0.0128) | 0.031 (± 0.0183) | |
| Basophils, Day 29: pre-dose, n=12, 13, 12 | 0.038 (± 0.0164) | 0.025 (± 0.012) | 0.027 (± 0.0161) | |
| Basophils, Day 29: 4 hr, n=12, 13, 11 | 0.032 (± 0.0103) | 0.028 (± 0.0215) | 0.027 (± 0.0127) | |
| Basophils, Day 32, n=12, 13, 10 | 0.038 (± 0.0094) | 0.026 (± 0.0119) | 0.031 (± 0.0238) | |

| | | | | |
|---|------------------|------------------|------------------|--|
| Basophils, Day 42, n=12, 13, 12 | 0.037 (± 0.0167) | 0.026 (± 0.0145) | 0.033 (± 0.0166) | |
| Basophils, Day 57, n=12, 13, 12 | 0.028 (± 0.0111) | 0.025 (± 0.0105) | 0.03 (± 0.0154) | |
| Basophils, Day 85, n=12, 13, 12 | 0.03 (± 0.0121) | 0.025 (± 0.0156) | 0.028 (± 0.0111) | |
| Basophils, Day 120, n=10, 13, 12 | 0.031 (± 0.012) | 0.035 (± 0.0181) | 0.031 (± 0.0151) | |
| Basophils, Day 165, n=12, 13, 12 | 0.035 (± 0.0162) | 0.037 (± 0.017) | 0.032 (± 0.0185) | |
| Basophils, follow-up, n=12, 13, 12 | 0.032 (± 0.0119) | 0.032 (± 0.0099) | 0.028 (± 0.019) | |
| Eosinophils, Screening, n=12, 12, 11 | 0.193 (± 0.1046) | 0.139 (± 0.0728) | 0.211 (± 0.1612) | |
| Eosinophils, Day 1: pre-dose, n=12, 13, 11 | 0.21 (± 0.1648) | 0.206 (± 0.1295) | 0.234 (± 0.1539) | |
| Eosinophils, Day 1: 4 hr, 12, 12, 11 | 0.157 (± 0.13) | 0.216 (± 0.2164) | 0.206 (± 0.1496) | |
| Eosinophils, Day 4, n=11, 12, 11 | 0.216 (± 0.1214) | 0.143 (± 0.0862) | 0.226 (± 0.1364) | |
| Eosinophils, Day 9, n=12, 13, 12 | 0.188 (± 0.106) | 0.188 (± 0.1166) | 0.288 (± 0.2169) | |
| Eosinophils, Day 14, n=12, 12, 12 | 0.228 (± 0.141) | 0.185 (± 0.0834) | 0.246 (± 0.1154) | |
| Eosinophils, Day 21, n=12, 13, 12 | 0.234 (± 0.1725) | 0.202 (± 0.1057) | 0.258 (± 0.1638) | |
| Eosinophils, Day 29: pre-dose, n=12, 13, 12 | 0.232 (± 0.218) | 0.198 (± 0.1514) | 0.209 (± 0.1396) | |
| Eosinophils, Day 29: 4 hr, n=12, 13, 11 | 0.205 (± 0.2068) | 0.211 (± 0.1413) | 0.18 (± 0.1096) | |
| Eosinophils, Day 32, n=12, 13, 10 | 0.193 (± 0.1321) | 0.204 (± 0.1183) | 0.254 (± 0.1767) | |
| Eosinophils, Day 42, n=12, 13, 12 | 0.219 (± 0.1439) | 0.18 (± 0.124) | 0.247 (± 0.1942) | |
| Eosinophils, Day 57, n=12, 13, 12 | 0.216 (± 0.1323) | 0.168 (± 0.115) | 0.239 (± 0.1647) | |
| Eosinophils, Day 85, n=12, 13, 12 | 0.226 (± 0.1479) | 0.161 (± 0.0867) | 0.242 (± 0.1591) | |
| Eosinophils, Day 120, n=10, 13, 12 | 0.252 (± 0.1578) | 0.185 (± 0.126) | 0.275 (± 0.2013) | |
| Eosinophils, Day 165, n=12, 13, 12 | 0.193 (± 0.124) | 0.178 (± 0.1133) | 0.235 (± 0.1278) | |
| Eosinophils, follow-up, n=12, 13, 12 | 0.184 (± 0.0738) | 0.219 (± 0.1547) | 0.233 (± 0.1667) | |
| Lymphocytes, Screening, n=12, 12, 11 | 2.317 (± 0.5927) | 1.953 (± 0.4253) | 2.091 (± 0.6873) | |
| Lymphocytes, Day 1: pre-dose, n=12, 13, 11 | 2.343 (± 0.6072) | 2.001 (± 0.5459) | 2.138 (± 0.5642) | |
| Lymphocytes, Day 1: 4 hr, n=12, 12, 11 | 2.518 (± 0.7608) | 2.204 (± 0.4915) | 2.525 (± 0.7586) | |
| Lymphocytes, Day 4, n=11, 12, 11 | 2.648 (± 0.7298) | 2.114 (± 0.471) | 2.466 (± 0.7101) | |
| Lymphocytes, Day 9, n=12, 13, 12 | 2.598 (± 0.6504) | 2.251 (± 0.5491) | 2.513 (± 0.9688) | |
| Lymphocytes, Day 14, n=12, 12, 12 | 2.527 (± 0.5543) | 2.185 (± 0.6946) | 2.554 (± 0.8373) | |
| Lymphocytes, Day 21, n=12, 13, 12 | 2.443 (± 0.6599) | 2.225 (± 0.5516) | 2.559 (± 0.8931) | |
| Lymphocytes, Day 29: pre-dose, n=12, 13, 12 | 2.291 (± 0.6079) | 1.948 (± 0.5789) | 2.204 (± 0.6951) | |
| Lymphocytes, Day 29: 4 hr, n=12, 13, 11 | 2.534 (± 0.919) | 2.446 (± 0.6275) | 2.535 (± 0.8419) | |

| | | | | |
|---|------------------|------------------|------------------|--|
| Lymphocytes, Day 32, n=12, 13, 10 | 2.428 (± 0.5944) | 2.102 (± 0.656) | 2.625 (± 0.6761) | |
| Lymphocytes, Day 42, n=12, 13, 12 | 2.28 (± 0.5761) | 2.063 (± 0.5239) | 2.384 (± 0.7138) | |
| Lymphocytes, Day 57, n=12, 13, 12 | 2.503 (± 0.5448) | 2.211 (± 0.5601) | 2.349 (± 0.8857) | |
| Lymphocytes, Day 85, n=12, 13, 12 | 2.324 (± 0.4915) | 2.126 (± 0.6184) | 2.413 (± 0.7779) | |
| Lymphocytes, Day 120, n=10, 13, 12 | 2.406 (± 0.3655) | 2.122 (± 0.6655) | 2.431 (± 0.6785) | |
| Lymphocytes, Day 165, n=12, 13, 12 | 2.481 (± 0.608) | 2.277 (± 0.6019) | 2.639 (± 0.965) | |
| Lymphocytes, follow-up, n=12, 13, 12 | 2.487 (± 0.5731) | 2.182 (± 0.5712) | 2.395 (± 0.9368) | |
| Monocytes, Screening, n=12, 12, 11 | 0.468 (± 0.1902) | 0.444 (± 0.1418) | 0.529 (± 0.1316) | |
| Monocytes, Day 1: pre-dose, n=12, 13, 11 | 0.452 (± 0.2115) | 0.41 (± 0.1112) | 0.591 (± 0.1929) | |
| Monocytes, Day 1: 4 hr, n=12, 12, 11 | 0.486 (± 0.2782) | 0.464 (± 0.1623) | 0.578 (± 0.2161) | |
| Monocytes, Day 4, n=11, 12, 11 | 0.564 (± 0.2131) | 0.451 (± 0.1527) | 0.553 (± 0.156) | |
| Monocytes, Day 9, n=12, 13, 12 | 0.551 (± 0.1814) | 0.445 (± 0.1359) | 0.601 (± 0.1812) | |
| Monocytes, Day 14, n=12, 12, 12 | 0.53 (± 0.153) | 0.412 (± 0.1216) | 0.567 (± 0.1654) | |
| Monocytes, Day 21, n=12, 13, 12 | 0.495 (± 0.2371) | 0.439 (± 0.1556) | 0.579 (± 0.1896) | |
| Monocytes, Day 29: pre-dose, n=12, 13, 12 | 0.52 (± 0.2108) | 0.412 (± 0.2101) | 0.483 (± 0.1345) | |
| Monocytes, Day 29: 4 hr, n=12, 13, 11 | 0.46 (± 0.2046) | 0.481 (± 0.2329) | 0.467 (± 0.1995) | |
| Monocytes, Day 32, n=12, 13, 10 | 0.524 (± 0.1996) | 0.427 (± 0.161) | 0.542 (± 0.1701) | |
| Monocytes, Day 42, n=12, 13, 12 | 0.508 (± 0.1889) | 0.437 (± 0.1413) | 0.526 (± 0.1477) | |
| Monocytes, Day 57, n=12, 13, 12 | 0.47 (± 0.1399) | 0.414 (± 0.1281) | 0.499 (± 0.1303) | |
| Monocytes, Day 85, n=12, 13, 12 | 0.503 (± 0.2007) | 0.412 (± 0.0966) | 0.505 (± 0.142) | |
| Monocytes, Day 120, n=10, 13, 12 | 0.503 (± 0.1905) | 0.451 (± 0.1327) | 0.561 (± 0.1402) | |
| Monocytes, Day 165, n=12, 13, 12 | 0.501 (± 0.1996) | 0.457 (± 0.1375) | 0.581 (± 0.1507) | |
| Monocytes, follow-up, n=12, 13, 12 | 0.518 (± 0.1865) | 0.437 (± 0.1496) | 0.562 (± 0.1711) | |
| SN, Screening, n=12, 12, 11 | 5.658 (± 1.3836) | 4.668 (± 0.6027) | 4.772 (± 0.9135) | |
| SN, Day 1: pre-dose, n=12, 13, 11 | 4.954 (± 1.4938) | 4.72 (± 0.6397) | 5.231 (± 1.0358) | |
| SN, Day 1: 4 hr, n=12, 12, 11 | 5.373 (± 1.3816) | 4.793 (± 1.0974) | 4.85 (± 1.1057) | |
| SN, Day 4, n=11, 12, 11 | 5.729 (± 2.5059) | 5.228 (± 2.6104) | 4.43 (± 1.0647) | |
| SN, Day 9, n=12, 13, 12 | 5.368 (± 1.9487) | 4.686 (± 0.8311) | 5.444 (± 2.7529) | |
| SN, Day 14, n=12, 12, 12 | 4.639 (± 1.524) | 4.373 (± 0.6839) | 4.836 (± 1.4616) | |
| SN, Day 21, n=12, 13, 12 | 5.059 (± 1.3648) | 4.536 (± 0.813) | 4.655 (± 1.9044) | |
| SN, Day 29: pre-dose, n=12, 13, 12 | 4.863 (± 1.2799) | 4.545 (± 1.3399) | 4.265 (± 0.9905) | |

| | | | | |
|---|-----------------------|-----------------------|-----------------------|--|
| SN, Day 29: 4 hr, n=12, 13, 11 | 4.793 (\pm 1.692) | 4.93 (\pm 1.7753) | 4.43 (\pm 0.8664) | |
| SN, Day 32, n=12, 13, 10 | 4.951 (\pm 1.2533) | 4.165 (\pm 0.776) | 4.642 (\pm 1.3905) | |
| SN, Day 42, n=12, 13, 12 | 4.608 (\pm 1.148) | 4.312 (\pm 1.4833) | 4.745 (\pm 2.1018) | |
| SN, Day 57, n=12, 13, 12 | 4.852 (\pm 1.6242) | 4.294 (\pm 0.7175) | 4.654 (\pm 1.0599) | |
| SN, Day 85, n=12, 13, 12 | 4.706 (\pm 1.5539) | 4.673 (\pm 1.0079) | 4.43 (\pm 1.1635) | |
| SN, Day 120, n=10, 13, 12 | 4.507 (\pm 1.1009) | 4.198 (\pm 0.9874) | 4.753 (\pm 1.7489) | |
| SN, Day 165, n=12, 13, 12 | 5.13 (\pm 2.0136) | 4.512 (\pm 0.9273) | 4.999 (\pm 2.0022) | |
| SN, follow-up, n=12, 13, 12 | 4.866 (\pm 1.4912) | 4.525 (\pm 0.6462) | 4.787 (\pm 1.592) | |
| TN, Screening, n=12, 12, 11 | 5.658 (\pm 1.3836) | 4.668 (\pm 0.6027) | 4.772 (\pm 0.9135) | |
| TN, Day 1: pre-dose, n=12, 13, 11 | 4.954 (\pm 1.4938) | 4.72 (\pm 0.6397) | 5.231 (\pm 1.0358) | |
| TN, Day 1: 4 hr, n=12, 12, 11 | 5.373 (\pm 1.3816) | 4.793 (\pm 1.0974) | 4.85 (\pm 1.1057) | |
| TN, Day 4, n=11, 12, 11 | 5.729 (\pm 2.5059) | 5.228 (\pm 2.6104) | 4.43 (\pm 1.0647) | |
| TN, Day 9, n=12, 13, 12 | 5.368 (\pm 1.9487) | 4.686 (\pm 0.8311) | 5.444 (\pm 2.7529) | |
| TN, Day 14, n=12, 12, 12 | 4.639 (\pm 1.524) | 4.373 (\pm 0.6839) | 4.836 (\pm 1.4616) | |
| TN, Day 21, n=12, 13, 12 | 5.059 (\pm 1.3648) | 4.536 (\pm 0.813) | 4.655 (\pm 1.9044) | |
| TN, Day 29: pre-dose, n=12, 13, 12 | 4.863 (\pm 1.2799) | 4.545 (\pm 1.3399) | 4.265 (\pm 0.9905) | |
| TN, Day 29: 4 hr, n=12, 13, 11 | 4.793 (\pm 1.692) | 4.93 (\pm 1.7753) | 4.43 (\pm 0.8664) | |
| TN, Day 32, n=12, 13, 10 | 4.951 (\pm 1.2533) | 4.165 (\pm 0.776) | 4.642 (\pm 1.3905) | |
| TN, Day 42, n=12, 13, 12 | 4.608 (\pm 1.148) | 4.312 (\pm 1.4833) | 4.745 (\pm 2.1018) | |
| TN, Day 57, n=12, 13, 12 | 4.852 (\pm 1.6242) | 4.294 (\pm 0.7175) | 4.654 (\pm 1.0599) | |
| TN, Day 85, n=12, 13, 12 | 4.706 (\pm 1.5539) | 4.673 (\pm 1.0079) | 4.43 (\pm 1.1635) | |
| TN, Day 120, n=10, 13, 12 | 4.507 (\pm 1.1009) | 4.198 (\pm 0.9874) | 4.753 (\pm 1.7489) | |
| TN, Day 165, n=12, 13, 12 | 5.13 (\pm 2.0136) | 4.512 (\pm 0.9273) | 4.999 (\pm 2.0022) | |
| TN, follow-up, n=12, 13, 12 | 4.866 (\pm 1.4912) | 4.525 (\pm 0.6462) | 4.787 (\pm 1.592) | |
| Platelet count, Screening, n=12, 12, 11 | 227.2 (\pm 75.31) | 242.3 (\pm 47.09) | 195.4 (\pm 43.98) | |
| Platelet count, Day 1: pre-dose, n=12, 13, 11 | 226.6 (\pm 60.08) | 234.2 (\pm 46.94) | 196.5 (\pm 46.74) | |
| Platelet count, Day 1: 4 hr, n=11, 12, 11 | 225.8 (\pm 56.85) | 235 (\pm 56.47) | 205.6 (\pm 37.71) | |
| Platelet count, Day 4, n=11, 12, 11 | 233.6 (\pm 48.43) | 258.7 (\pm 48.85) | 214.8 (\pm 51.29) | |
| Platelet count, Day 9, n=12, 13, 12 | 228 (\pm 58.56) | 249.2 (\pm 47.53) | 209 (\pm 53.27) | |
| Platelet count, Day 14, n=12, 13, 12 | 236.1 (\pm 59.29) | 238.5 (\pm 46.69) | 222.8 (\pm 61.53) | |
| Platelet count, Day 21, n=12, 13, 12 | 238.2 (\pm 61.79) | 244.2 (\pm 43.88) | 199.9 (\pm 63.66) | |

| | | | |
|--|-----------------|-----------------|-----------------|
| Platelet count, Day 29: pre-dose, n=12, 12, 12 | 224.6 (± 57.84) | 237 (± 62.61) | 185.8 (± 50.99) |
| Platelet count, Day 29: 4 hr, n=12, 13, 11 | 221.4 (± 64.4) | 237.8 (± 47.91) | 180.9 (± 55.12) |
| Platelet count, Day 32, n=12, 13, 10 | 240.6 (± 63.98) | 249.2 (± 50.03) | 209.4 (± 53.34) |
| Platelet count, Day 42, n=12, 13, 12 | 234 (± 62.46) | 251.8 (± 49.72) | 201.9 (± 41.39) |
| Platelet count, Day 57, n=12, 12, 12 | 225.7 (± 67.79) | 237.1 (± 60.1) | 192.3 (± 35.73) |
| Platelet count, Day 85, n=12, 12, 11 | 221.8 (± 56.57) | 244.2 (± 60.92) | 200.2 (± 44.46) |
| Platelet count, Day 120, n=10, 13, 12 | 235.2 (± 54.93) | 241.5 (± 52.38) | 203.4 (± 54.48) |
| Platelet count, Day 165, n=12, 13, 12 | 232.5 (± 57.26) | 255.6 (± 59.77) | 204.3 (± 58) |
| Platelet count, follow-up, n=12, 13, 12 | 244.5 (± 56.29) | 249.5 (± 51.44) | 212.2 (± 57.93) |
| WBC count, Screening, n=12, 12, 11 | 8.67 (± 1.815) | 7.23 (± 0.757) | 7.62 (± 1.494) |
| WBC count, Day 1: pre-dose, n=12, 13, 11 | 8 (± 1.982) | 7.36 (± 0.991) | 8.21 (± 1.662) |
| WBC count, Day 1: 4 hr, n=12, 12, 11 | 8.58 (± 1.863) | 7.7 (± 1.149) | 8.17 (± 1.532) |
| WBC count, Day 4, n=11, 12, 11 | 9.21 (± 2.841) | 7.98 (± 2.817) | 7.71 (± 1.624) |
| WBC count, Day 9, n=12, 12, 12 | 8.74 (± 2.499) | 7.6 (± 1.211) | 8.88 (± 3.038) |
| WBC count, Day 14, n=12, 13, 12 | 7.97 (± 1.835) | 7.18 (± 1.257) | 8.23 (± 1.855) |
| WBC count, Day 21, n=12, 13, 12 | 8.26 (± 1.856) | 7.45 (± 1.2) | 8.08 (± 2.369) |
| WBC count, Day 29: pre-dose, n=12, 13, 12 | 7.94 (± 1.681) | 7.13 (± 1.66) | 7.2 (± 1.591) |
| WBC count, Day 29: 4 hr, n=12, 13, 11 | 8.02 (± 1.794) | 8.1 (± 1.626) | 7.65 (± 1.457) |
| WBC count, Day 32, n=12, 13, 10 | 8.13 (± 1.766) | 6.92 (± 1.114) | 8.11 (± 2.221) |
| WBC count, Day 42, n=12, 13, 12 | 7.65 (± 1.645) | 7.02 (± 1.81) | 7.94 (± 2.696) |
| WBC count, Day 57, n=12, 13, 12 | 8.08 (± 2.065) | 7.12 (± 1.094) | 7.78 (± 1.796) |
| WBC count, Day 85, n=12, 13, 11 | 7.79 (± 1.891) | 7.38 (± 1.409) | 7.62 (± 1.823) |
| WBC count, Day 120, n=10, 13, 12 | 7.69 (± 1.339) | 7 (± 1.348) | 8.06 (± 2.21) |
| WBC count, Day 165, n=12, 13, 12 | 8.34 (± 2.567) | 7.47 (± 1.386) | 8.48 (± 2.975) |
| WBC count, follow-up, n=12, 13, 12 | 8.08 (± 1.875) | 7.39 (± 1.054) | 8.01 (± 2.012) |

Notes:

[28] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[29] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[30] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Hemoglobin and mean corpuscle hemoglobin concentration (MCHC) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|------------------------|--|
| End point title | Hemoglobin and mean corpuscle hemoglobin concentration (MCHC) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
| End point description: | Hemoglobin and MCHC values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up. |
| End point type | Secondary |

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[31] | 13 ^[32] | 12 ^[33] | |
| Units: Grams per liter (G/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Hemoglobin, Screening, n=12, 12, 11 | 156.8 (± 17.52) | 149.6 (± 18.31) | 149.1 (± 9.98) | |
| Hemoglobin, Day 1: pre-dose, n=12, 13, 11 | 150.8 (± 14.28) | 145.3 (± 17.72) | 144.7 (± 9.1) | |
| Hemoglobin, Day 1: 4 hr, n=12, 12, 11 | 145.3 (± 12.11) | 139.1 (± 12.65) | 137.5 (± 7.57) | |
| Hemoglobin, Day 4, n=11, 12, 11 | 152.8 (± 16.33) | 142.8 (± 16.26) | 143 (± 8.41) | |
| Hemoglobin, Day 9, n=12, 13, 12 | 152.7 (± 14.12) | 143.2 (± 17.2) | 141.4 (± 10.18) | |
| Hemoglobin, Day 14, n=12, 13, 12 | 152.8 (± 13.74) | 143.2 (± 16.47) | 142.1 (± 9.34) | |
| Hemoglobin, Day 21, n=12, 13, 12 | 152 (± 13.75) | 144.3 (± 16.99) | 142.4 (± 11.07) | |
| Hemoglobin, Day 29: pre-dose, n=12, 13, 12 | 148.4 (± 13.63) | 139.8 (± 17.51) | 139.8 (± 11.69) | |
| Hemoglobin, Day 29: 4 hr, n=12, 13, 11 | 145.3 (± 14.12) | 139.7 (± 17.14) | 135.6 (± 8.63) | |
| Hemoglobin, Day 32, n=12, 13, 10 | 148.5 (± 12.52) | 140.9 (± 17.26) | 141.5 (± 11.34) | |
| Hemoglobin, Day 42, n=12, 13, 12 | 149.4 (± 12.65) | 140.9 (± 17.07) | 140.4 (± 11.08) | |
| Hemoglobin, Day 57, n=12, 13, 12 | 149.9 (± 13.7) | 140.2 (± 17.51) | 141 (± 11.95) | |
| Hemoglobin, Day 85, n=12, 13, 12 | 150.5 (± 16.28) | 142.5 (± 16.57) | 139 (± 11.1) | |
| Hemoglobin, Day 120, n=10, 13, 12 | 151.4 (± 17.37) | 142.3 (± 20.33) | 141.9 (± 13.96) | |
| Hemoglobin, Day 165, n=12, 13, 12 | 150.6 (± 15.62) | 142.5 (± 20.28) | 140.3 (± 13.72) | |
| Hemoglobin, follow-up, n=12, 13, 12 | 151.3 (± 14.69) | 142.1 (± 22.08) | 139.8 (± 12.63) | |
| MCHC, Screening, n=12, 12, 11 | 326.6 (± 9.06) | 324.4 (± 7.86) | 327.4 (± 11.29) | |
| MCHC, Day 1: pre-dose, n=12, 13, 11 | 326.6 (± 7.69) | 322.8 (± 10.43) | 327.6 (± 10.06) | |
| MCHC, Day 1: 4 hr, n=12, 12, 11 | 325 (± 6.52) | 320.8 (± 11.26) | 326.5 (± 7.83) | |
| MCHC, Day 4, n=11, 12, 11 | 326.4 (± 10.54) | 325.8 (± 8.08) | 327.4 (± 6.44) | |
| MCHC, Day 9, n=12, 13, 12 | 328.5 (± 11.21) | 323.3 (± 6.51) | 327.7 (± 11.48) | |
| MCHC, Day 14, n=12, 13, 12 | 325.2 (± 8.39) | 325.1 (± 9.73) | 328.8 (± 7.69) | |
| MCHC, Day 21, n=12, 13, 12 | 325.3 (± 8.76) | 324.3 (± 6.34) | 326.5 (± 6.74) | |
| MCHC, Day 29: pre-dose, n=12, 13, 12 | 326 (± 11.1) | 320.1 (± 11.75) | 320.8 (± 13.04) | |

| | | | | |
|----------------------------------|-----------------|-----------------|-----------------|--|
| MCHC, Day 29: 4 hr, n=12, 13, 11 | 323 (± 7.16) | 318.6 (± 10.34) | 323.1 (± 11.67) | |
| MCHC, Day 32, n=12, 13, 10 | 326.9 (± 11.47) | 323.2 (± 8.98) | 325.1 (± 6.3) | |
| MCHC, Day 42, n=12, 13, 12 | 324.8 (± 9.61) | 321.5 (± 10.96) | 322.6 (± 9.1) | |
| MCHC, Day 57, n=12, 13, 12 | 323.8 (± 11.34) | 321.2 (± 9.55) | 323.2 (± 6.45) | |
| MCHC, Day 85, n=12, 13, 12 | 323.2 (± 10.22) | 317.8 (± 8.27) | 320.2 (± 7.4) | |
| MCHC, Day 120, n=10, 13, 12 | 321.3 (± 7.59) | 319 (± 9.49) | 319.8 (± 7.85) | |
| MCHC, Day 165, n=12, 13, 12 | 322.4 (± 9.77) | 318.9 (± 7.24) | 319 (± 6.81) | |
| MCHC, follow-up, n=12, 13, 12 | 319.3 (± 11.52) | 318.8 (± 8.86) | 319 (± 9.12) | |

Notes:

[31] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[32] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[33] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Hematocrit values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Hematocrit values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

Hematocrit values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[34] | 13 ^[35] | 12 ^[36] | |
| Units: Proportion of red blood cells in blood | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening, n=12, 12, 11 | 0.4799 (± 0.05006) | 0.461 (± 0.05737) | 0.4555 (± 0.03407) | |
| Day 1: pre-dose, n=12, 13, 11 | 0.4607 (± 0.03855) | 0.4504 (± 0.05399) | 0.4419 (± 0.03158) | |
| Day 1: 4 hr, n=12, 12, 11 | 0.4468 (± 0.03652) | 0.4341 (± 0.04154) | 0.4214 (± 0.02543) | |
| Day 4, n=11, 12, 11 | 0.4682 (± 0.05106) | 0.4387 (± 0.05038) | 0.4371 (± 0.02468) | |
| Day 9, n=12, 13, 12 | 0.4649 (± 0.04146) | 0.4432 (± 0.05507) | 0.4315 (± 0.03044) | |

| | | | | |
|--------------------------------|--------------------|--------------------|--------------------|--|
| Day 14, n=12, 13, 12 | 0.4701 (± 0.03889) | 0.4408 (± 0.05164) | 0.4321 (± 0.02489) | |
| Day 21, n=12, 13, 12 | 0.4673 (± 0.04176) | 0.4454 (± 0.05511) | 0.4364 (± 0.03362) | |
| Day 29: pre-dose, n=12, 13, 12 | 0.4551 (± 0.03785) | 0.4368 (± 0.04971) | 0.4361 (± 0.03512) | |
| Day 29: 4 hr, n=12, 13, 11 | 0.45 (± 0.04137) | 0.4385 (± 0.05347) | 0.4197 (± 0.02605) | |
| Day 32, n=12, 13, 10 | 0.4547 (± 0.03776) | 0.4361 (± 0.05536) | 0.4354 (± 0.03389) | |
| Day 42, n=12, 13, 12 | 0.4609 (± 0.04166) | 0.4387 (± 0.0532) | 0.4353 (± 0.03217) | |
| Day 57, n=12, 13, 12 | 0.4628 (± 0.03985) | 0.4368 (± 0.05354) | 0.4366 (± 0.03679) | |
| Day 85, n=12, 13, 12 | 0.4653 (± 0.04823) | 0.4483 (± 0.05264) | 0.4345 (± 0.0368) | |
| Day 120, n=10, 13, 12 | 0.4717 (± 0.05091) | 0.4457 (± 0.06294) | 0.4442 (± 0.04487) | |
| Day 165, n=12, 13, 12 | 0.4676 (± 0.04512) | 0.4458 (± 0.05822) | 0.4394 (± 0.04186) | |
| Follow-up, n=12, 13, 12 | 0.4733 (± 0.03656) | 0.4454 (± 0.06752) | 0.4381 (± 0.03863) | |

Notes:

[34] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[35] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[36] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Mean corpuscle hemoglobin (MCH) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Mean corpuscle hemoglobin (MCH) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

MCH values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[37] | 13 ^[38] | 12 ^[39] | |
| Units: Picograms | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening, n=12, 12, 11 | 30.46 (± 1.743) | 29.58 (± 1.736) | 31.35 (± 2.23) | |
| Day 1: pre-dose, n=12, 13, 11 | 30.67 (± 1.793) | 29.76 (± 1.531) | 31.1 (± 2.385) | |

| | | | | |
|--------------------------------|-----------------|-----------------|-----------------|--|
| Day 1: 4 hr, n=12, 12, 11 | 30.78 (± 1.88) | 29.53 (± 1.555) | 30.64 (± 1.967) | |
| Day 4, n=11, 12, 11 | 30.74 (± 1.989) | 29.68 (± 1.73) | 31.02 (± 2.101) | |
| Day 9, n=12, 13, 12 | 30.8 (± 1.805) | 29.57 (± 1.625) | 31.05 (± 2.345) | |
| Day 14, n=12, 13, 12 | 30.52 (± 1.7) | 29.83 (± 1.666) | 31.03 (± 2.214) | |
| Day 21, n=12, 13, 12 | 30.58 (± 1.693) | 29.68 (± 1.496) | 30.89 (± 2.381) | |
| Day 29: pre-dose, n=12, 13, 12 | 30.74 (± 1.931) | 29.5 (± 1.694) | 30.58 (± 2.482) | |
| Day 29: 4 hr, n=12, 13, 11 | 30.62 (± 1.712) | 29.58 (± 1.585) | 31.05 (± 2.649) | |
| Day 32, n=12, 13, 10 | 30.69 (± 1.834) | 29.6 (± 1.759) | 30.59 (± 2.227) | |
| Day 42, n=12, 13, 12 | 30.48 (± 1.698) | 29.42 (± 1.672) | 30.68 (± 2.51) | |
| Day 57, n=12, 13, 12 | 30.37 (± 1.861) | 29.42 (± 1.912) | 30.63 (± 2.623) | |
| Day 85, n=12, 13, 12 | 30.15 (± 1.822) | 28.98 (± 1.983) | 30.33 (± 2.5) | |
| Day 120, n=10, 13, 12 | 29.72 (± 2.059) | 28.93 (± 2.197) | 29.94 (± 2.405) | |
| Day 165, n=12, 13, 12 | 29.67 (± 2.195) | 28.62 (± 2.378) | 29.27 (± 2.597) | |
| Follow-up, n=12, 13, 12 | 29.49 (± 2.198) | 28.62 (± 2.3) | 29.51 (± 2.652) | |

Notes:

[37] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[38] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[39] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Mean corpuscle volume (MCV) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Mean corpuscle volume (MCV) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

MCV values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[40] | 13 ^[41] | 12 ^[42] | |
| Units: Femtoliters | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening, n=12, 12, 11 | 93.3 (± 4.74) | 91.3 (± 4.25) | 95.7 (± 5.22) | |
| Day 1: pre-dose, n=12, 13, 11 | 94 (± 4.67) | 92.3 (± 4.48) | 95 (± 5.8) | |
| Day 1: 4 hr, n=12, 12, 11 | 94.7 (± 4.83) | 92 (± 4.11) | 94 (± 4.2) | |
| Day 4, n=11, 12, 11 | 94 (± 4.6) | 91.3 (± 4.59) | 94.7 (± 6.21) | |
| Day 9, n=12, 13, 12 | 93.6 (± 4.74) | 91.4 (± 3.91) | 94.8 (± 5.72) | |
| Day 14, n=12, 13, 12 | 94 (± 4.39) | 91.8 (± 4.52) | 94.4 (± 6.87) | |
| Day 21, n=12, 13, 12 | 94.2 (± 3.97) | 91.6 (± 4.65) | 94.7 (± 6.5) | |
| Day 29: pre-dose, n=12, 13, 12 | 94.3 (± 4.44) | 92.2 (± 5.32) | 95.4 (± 6.89) | |
| Day 29: 4 hr, n=12, 13, 11 | 94.8 (± 4.81) | 93 (± 5.12) | 96.1 (± 6.88) | |
| Day 32, n=12, 13, 10 | 93.9 (± 4.25) | 91.6 (± 4.21) | 94.1 (± 7.13) | |
| Day 42, n=12, 13, 12 | 93.8 (± 3.93) | 91.5 (± 4.99) | 95.2 (± 7.23) | |
| Day 57, n=12, 13, 12 | 93.8 (± 4.11) | 91.6 (± 4.84) | 94.9 (± 7.46) | |
| Day 85, n=12, 13, 12 | 93.3 (± 3.87) | 91.2 (± 5.12) | 94.8 (± 6.98) | |
| Day 120, n=10, 13, 12 | 92.6 (± 5.04) | 90.8 (± 5.82) | 93.7 (± 6.17) | |
| Day 165, n=12, 13, 12 | 92 (± 5.67) | 89.8 (± 5.85) | 91.8 (± 6.63) | |
| Follow-up, n=12, 13, 12 | 92.3 (± 5.61) | 89.8 (± 5.6) | 92.3 (± 6.77) | |

Notes:

[40] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[41] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[42] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Red blood cell (RBC) count values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Red blood cell (RBC) count values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

RBC count values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[43] | 13 ^[44] | 12 ^[45] | |
| Units: 10 ¹² cells per liter (TI/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening, n=12, 12, 11 | 5.16 (± 0.568) | 5.06 (± 0.661) | 4.77 (± 0.473) | |
| Day 1: pre-dose, n=12, 13, 11 | 4.92 (± 0.449) | 4.89 (± 0.595) | 4.68 (± 0.5) | |
| Day 1: 4 hr, n=12, 12, 11 | 4.72 (± 0.404) | 4.73 (± 0.449) | 4.5 (± 0.412) | |
| Day 4, n=11, 12, 11 | 4.97 (± 0.471) | 4.83 (± 0.583) | 4.64 (± 0.437) | |
| Day 9, n=12, 13, 12 | 4.98 (± 0.411) | 4.85 (± 0.613) | 4.59 (± 0.523) | |
| Day 14, n=12, 13, 12 | 5.01 (± 0.365) | 4.8 (± 0.564) | 4.61 (± 0.542) | |
| Day 21, n=12, 13, 12 | 4.97 (± 0.384) | 4.88 (± 0.596) | 4.66 (± 0.611) | |
| Day 29: pre-dose, n=12, 13, 12 | 4.85 (± 0.368) | 4.74 (± 0.55) | 4.61 (± 0.598) | |
| Day 29: 4 hr, n=12, 13, 11 | 4.76 (± 0.378) | 4.73 (± 0.545) | 4.4 (± 0.506) | |
| Day 32, n=10, 13, 10 | 4.85 (± 0.361) | 4.76 (± 0.605) | 4.66 (± 0.572) | |
| Day 42, n=12, 13, 12 | 4.92 (± 0.404) | 4.8 (± 0.557) | 4.63 (± 0.645) | |
| Day 57, n=12, 13, 12 | 4.96 (± 0.408) | 4.78 (± 0.564) | 4.65 (± 0.664) | |
| Day 85, n=12, 13, 12 | 4.98 (± 0.427) | 4.92 (± 0.537) | 4.62 (± 0.608) | |
| Day 120, n=10, 13, 12 | 5.1 (± 0.478) | 4.93 (± 0.612) | 4.77 (± 0.679) | |
| Day 165, n=12, 13, 12 | 5.09 (± 0.36) | 4.98 (± 0.554) | 4.82 (± 0.671) | |
| Follow-up, n=12, 13, 12 | 5.15 (± 0.34) | 4.97 (± 0.687) | 4.79 (± 0.637) | |

Notes:

[43] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[44] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[45] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

SBP and DBP values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[46] | 13 ^[47] | 12 ^[48] | |
| Units: Millimeters of mercury (mmHg) | | | | |
| arithmetic mean (standard deviation) | | | | |
| SBP, Screening | 141.9 (± 14.12) | 139.7 (± 15.11) | 145.5 (± 14.37) | |
| SBP, Day 1: pre-dose | 141.5 (± 6.78) | 139.2 (± 11.68) | 140.9 (± 16.41) | |
| SBP, Day 1: 4 hr | 139.7 (± 16.09) | 139.8 (± 8.8) | 138 (± 16.14) | |
| SBP, Day 4 | 140 (± 12.99) | 137.5 (± 18.45) | 141.5 (± 10.94) | |
| SBP, Day 9 | 136.3 (± 14.33) | 137.3 (± 20.86) | 140.4 (± 18.66) | |
| SBP, Day 14 | 139.2 (± 12.43) | 136.9 (± 15.12) | 135.9 (± 21) | |
| SBP, Day 21 | 133.1 (± 16.03) | 142.3 (± 14.99) | 139.9 (± 11.67) | |
| SBP, Day 29: pre-dose | 133.9 (± 13.94) | 139 (± 17) | 140.7 (± 9.73) | |
| SBP, Day 29: 4 hr | 132.6 (± 11.98) | 141.2 (± 17.39) | 146.5 (± 12.7) | |
| SBP, Day 32 | 137.4 (± 14.11) | 136.1 (± 13.02) | 143.5 (± 13.86) | |
| SBP, Day 42 | 134.8 (± 15.46) | 137.4 (± 16.48) | 135.3 (± 18.4) | |
| SBP, Day 57 | 136.7 (± 12.99) | 134.8 (± 15.59) | 133.3 (± 12.15) | |
| SBP, Day 85 | 133.8 (± 14.54) | 138.3 (± 11.56) | 140 (± 11.69) | |
| SBP, Day 120 | 132.1 (± 15.68) | 134.2 (± 13.47) | 147.2 (± 11.27) | |
| SBP, Day 165 | 131.7 (± 17.33) | 136.2 (± 13.53) | 137.9 (± 17.05) | |
| SBP, follow-up | 131.9 (± 14.2) | 139.3 (± 14.44) | 137.3 (± 13.36) | |
| DBP, Screening | 85.3 (± 5.37) | 84.5 (± 8.38) | 85.4 (± 7.45) | |
| DBP, Day 1: pre-dose | 84.3 (± 8.85) | 81.8 (± 6.31) | 80.4 (± 8.73) | |
| DBP, Day 1: 4 hr | 80.8 (± 7.09) | 80.5 (± 5.01) | 77.7 (± 11.08) | |
| DBP, Day 4 | 82.6 (± 8.01) | 77.6 (± 9.42) | 82.7 (± 6.83) | |
| DBP, Day 9 | 80.5 (± 7.27) | 80.5 (± 8.81) | 81.8 (± 7.44) | |
| DBP, Day 14 | 84.3 (± 7.33) | 79.9 (± 6.75) | 76.5 (± 14.81) | |
| DBP, Day 21 | 80.8 (± 6.04) | 81.4 (± 6.13) | 77.2 (± 9.28) | |
| DBP, Day 29: pre-dose | 80.1 (± 9.55) | 83.1 (± 11) | 81.8 (± 8.44) | |
| DBP, Day 29: 4 hr | 77.4 (± 7.66) | 80.3 (± 7.38) | 79.2 (± 8.55) | |
| DBP, Day 32 | 80.8 (± 8.62) | 80.2 (± 6.26) | 80 (± 12.67) | |
| DBP, Day 42 | 79.3 (± 4.85) | 79.2 (± 8.02) | 77.3 (± 10.25) | |
| DBP, Day 57 | 81.3 (± 8.09) | 77.5 (± 7.08) | 79.2 (± 9.72) | |
| DBP, Day 85 | 77.8 (± 8.09) | 81.6 (± 8.44) | 76 (± 7.45) | |
| DBP, Day 120 | 81.5 (± 7.15) | 78.9 (± 5.17) | 85.6 (± 7.28) | |
| DBP, Day 165 | 79.1 (± 9.73) | 79.8 (± 9.33) | 80.3 (± 9.38) | |
| DBP, follow-up | 81.2 (± 9.25) | 81 (± 7.31) | 80.1 (± 8.66) | |

Notes:

[46] - All Subject Population

[47] - All Subject Population

[48] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Heart rate (HR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Heart rate (HR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

HR values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[49] | 13 ^[50] | 12 ^[51] | |
| Units: Beats per minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening | 71.5 (± 9.49) | 77.8 (± 12.62) | 74.8 (± 9.18) | |
| Day 1: pre-dose | 72.8 (± 6.73) | 79.9 (± 10.7) | 72.3 (± 7.63) | |
| Day 1: 4 hr | 74.1 (± 11.37) | 79.2 (± 10.64) | 74.2 (± 10.03) | |
| Day 4 | 73.6 (± 8.27) | 78.9 (± 15.53) | 72.9 (± 8.26) | |
| Day 9 | 69.7 (± 9.26) | 76.3 (± 11.24) | 74.8 (± 14.45) | |
| Day 14 | 71.2 (± 11.64) | 77.4 (± 9.63) | 74.8 (± 9.2) | |
| Day 21 | 69 (± 9.17) | 77.6 (± 9.25) | 72.7 (± 11.04) | |
| Day 29: pre-dose | 70.3 (± 9.19) | 78.3 (± 11.13) | 69.5 (± 7) | |
| Day 29: 4 hr | 72.4 (± 10.23) | 82.2 (± 12.05) | 72.1 (± 10.44) | |
| Day 32 | 69.6 (± 10.19) | 78 (± 10.52) | 71.7 (± 11.06) | |
| Day 42 | 69.4 (± 11.29) | 75.2 (± 11.63) | 72.8 (± 14.48) | |
| Day 57 | 70.5 (± 9.44) | 76.3 (± 11.66) | 71.3 (± 10.03) | |
| Day 85 | 70.1 (± 8.86) | 78.5 (± 10.32) | 70.3 (± 4.83) | |
| Day 120 | 67.3 (± 9.72) | 76.5 (± 10.07) | 74 (± 13.1) | |
| Day 165 | 70.1 (± 10.32) | 77.1 (± 11.21) | 73.8 (± 9.37) | |
| Follow-up | 69.2 (± 10.85) | 75.5 (± 12.37) | 71.4 (± 10.5) | |

Notes:

[49] - All Subject Population

[50] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Respiration rate (RR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Respiration rate (RR) values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

RR values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[52] | 13 ^[53] | 12 ^[54] | |
| Units: breaths per minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening | 16 (± 2.52) | 16.3 (± 3.22) | 17.2 (± 2.41) | |
| Day 1: pre-dose | 16 (± 2.34) | 15.8 (± 2.51) | 17.2 (± 2.44) | |
| Day 1: 4 hr | 17.8 (± 3.05) | 15.9 (± 3.9) | 18.2 (± 3.83) | |
| Day 4 | 15.5 (± 1.83) | 15.5 (± 2.63) | 17.3 (± 2.96) | |
| Day 9 | 16.6 (± 2.91) | 15.6 (± 2.53) | 16.7 (± 2.15) | |
| Day 14 | 16.3 (± 2.42) | 15.1 (± 3.09) | 16.7 (± 2.1) | |
| Day 21 | 15.6 (± 2.8) | 15.2 (± 2.73) | 16.9 (± 2.39) | |
| Day 29: pre-dose | 16.7 (± 2.71) | 15.4 (± 2.53) | 17.7 (± 3.31) | |
| Day 29: 4 hr | 16.9 (± 3.63) | 15.9 (± 4.25) | 18.7 (± 3.68) | |
| Day 32 | 15.9 (± 2.5) | 14.8 (± 3.08) | 16.8 (± 2.45) | |
| Day 42 | 15.6 (± 2.75) | 15 (± 2.94) | 17.8 (± 3.07) | |
| Day 57 | 15.8 (± 2.08) | 15.3 (± 2.75) | 17.2 (± 2.41) | |
| Day 85 | 16.2 (± 1.9) | 15 (± 2.08) | 17 (± 2.09) | |
| Day 120 | 16.3 (± 1.71) | 15.5 (± 2.47) | 16.5 (± 2.43) | |
| Day 165 | 16.3 (± 1.87) | 15.4 (± 2.06) | 16.2 (± 2.21) | |
| Follow-up | 16.1 (± 1.98) | 14.6 (± 2.18) | 16.3 (± 1.54) | |

Notes:

[52] - All Subject Population

[53] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Body temperature values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|---|
| End point title | Body temperature values at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|---|

End point description:

Body temperature values were assessed at Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening; Days 1 (pre-dose and 4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[55] | 13 ^[56] | 12 ^[57] | |
| Units: Degrees centigrade | | | | |
| arithmetic mean (standard deviation) | | | | |
| Screening | 35.98 (± 0.449) | 36.22 (± 0.436) | 35.87 (± 0.764) | |
| Day 1: pre-dose | 35.85 (± 0.403) | 35.93 (± 0.501) | 35.9 (± 0.558) | |
| Day 1: 4 hr | 36.33 (± 0.374) | 36.06 (± 0.415) | 36.07 (± 0.733) | |
| Day 4 | 35.91 (± 0.287) | 36.07 (± 0.494) | 35.98 (± 0.583) | |
| Day 9 | 35.74 (± 0.511) | 36.06 (± 0.715) | 35.96 (± 0.673) | |
| Day 14 | 35.83 (± 0.566) | 35.82 (± 0.483) | 35.93 (± 0.409) | |
| Day 21 | 35.94 (± 0.329) | 35.83 (± 0.545) | 35.98 (± 0.447) | |
| Day 29: pre-dose | 35.89 (± 0.378) | 35.81 (± 0.386) | 36 (± 0.531) | |
| Day 29: 4 hr | 36.13 (± 0.611) | 36.09 (± 0.448) | 35.92 (± 0.517) | |
| Day 32 | 35.71 (± 0.32) | 35.88 (± 0.554) | 35.78 (± 0.546) | |
| Day 42 | 35.82 (± 0.379) | 35.91 (± 0.206) | 36.01 (± 0.507) | |
| Day 57 | 35.81 (± 0.454) | 35.97 (± 0.473) | 35.83 (± 0.697) | |

| | | | | |
|-----------|-----------------|-----------------|-----------------|--|
| Day 85 | 35.77 (± 0.274) | 35.65 (± 0.448) | 35.84 (± 0.56) | |
| Day 120 | 35.93 (± 0.293) | 35.97 (± 0.312) | 35.58 (± 0.636) | |
| Day 165 | 35.78 (± 0.331) | 36.01 (± 0.441) | 35.6 (± 0.673) | |
| Follow-up | 35.8 (± 0.313) | 36.03 (± 0.357) | 35.74 (± 0.611) | |

Notes:

[55] - All Subject Population

[56] - All Subject Population

[57] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Electrocardiogram (ECG) measurements at Screening, Day 1 (pre-dose and 1 hr and 4 hr post-dose), and Day 29 (pre-dose and 1 hr and 4 hr post-dose)

| | |
|-----------------|--|
| End point title | Electrocardiogram (ECG) measurements at Screening, Day 1 (pre-dose and 1 hr and 4 hr post-dose), and Day 29 (pre-dose and 1 hr and 4 hr post-dose) |
|-----------------|--|

End point description:

ECG measurements included PR interval, QRS duration, QT interval, corrected QT (QTc) interval, corrected QT by Bazett's formula (QTcB) interval, corrected QT by Fridericia's formula (QTcF) interval, and RR interval.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Screening, Day 1 (pre-dose; 1 and 4 hr post-dose), and Day 29 (pre-dose; 1 hr and 4 hr post-dose)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[58] | 13 ^[59] | 12 ^[60] | |
| Units: milliseconds | | | | |
| arithmetic mean (standard deviation) | | | | |
| PR Interval, Screening, n=12, 13, 11 | 160.1 (± 32.8) | 162.7 (± 19.55) | 163.7 (± 19.84) | |
| PR Interval, Day 1: pre-dose, n=12, 13, 11 | 167.9 (± 25.29) | 170.4 (± 16.16) | 160.5 (± 19.23) | |
| PR Interval, Day 1: 1 hr, n=12, 13, 11 | 166.2 (± 27.83) | 169.5 (± 18.96) | 162.6 (± 17.38) | |
| PR Interval, Day 1: 4 hr, n=12, 13, 11 | 167 (± 32.19) | 164.9 (± 18.2) | 164.5 (± 22.11) | |
| PR Interval, Day 29, pre-dose, n=12, 13, 11 | 167.1 (± 35.51) | 163.4 (± 15.22) | 159.8 (± 30.41) | |
| PR Interval, Day 29: 1 hr, n=12, 13, 11 | 156.8 (± 35.19) | 171.8 (± 15.58) | 159.3 (± 31.05) | |
| PR Interval, Day 29: 4 hr, n=12, 13, 11 | 162.2 (± 37.64) | 167.7 (± 20.36) | 159.4 (± 32.06) | |
| QRS duration, Screening, n=12, 13, 12 | 105.8 (± 28.17) | 94.2 (± 24.15) | 102.9 (± 18.66) | |
| QRS duration, Day 1: pre-dose, n=12, 13, 12 | 101.6 (± 27.56) | 93.5 (± 23.99) | 103.6 (± 15.04) | |

| | | | |
|--|-----------------|-----------------|-----------------|
| QRS duration, Day 1: 1 hr, n=12, 13, 12 | 105.5 (± 29.18) | 94.2 (± 23.5) | 98.9 (± 15.83) |
| QRS duration, Day 1: 4 hr, n=12, 13, 12 | 104.4 (± 28.81) | 92.3 (± 26.7) | 103.9 (± 15.13) |
| QRS duration, Day 29, pre-dose, n=12, 12, 12 | 103.2 (± 28.9) | 92.8 (± 24.08) | 101.8 (± 12.76) |
| QRS duration, Day 29: 1 hr, n=12, 13, 12 | 103.1 (± 27.87) | 96.4 (± 22.34) | 101.3 (± 19.14) |
| QRS duration, Day 29: 4 hr, n=12, 13, 12 | 104.5 (± 26.06) | 95.8 (± 23.96) | 102.5 (± 16.19) |
| QT interval, Screening, n=12, 13, 12 | 377.6 (± 41.54) | 365.2 (± 32.26) | 385.6 (± 28.38) |
| QT interval, Day 1: pre-dose, n=12, 13, 12 | 390.8 (± 31.12) | 356.7 (± 28.42) | 380.8 (± 24.44) |
| QT interval, Day 1: 1 hr, n=12, 13, 12 | 389.1 (± 33.1) | 362.8 (± 34.09) | 386 (± 27.82) |
| QT interval, Day 1: 4 hr, n=12, 13, 12 | 374.6 (± 43.03) | 345.5 (± 30.49) | 374.6 (± 28.88) |
| QT interval, Day 29, pre-dose, n=12, 12, 12 | 379.9 (± 35.08) | 353.8 (± 20.36) | 382.2 (± 23.59) |
| QT interval, Day 29: 1 hr, n=12, 13, 12 | 393.4 (± 36.63) | 368.1 (± 32.66) | 386.1 (± 33.29) |
| QT interval, Day 29: 4 hr, n=12, 13, 12 | 378.8 (± 33.13) | 356.2 (± 29.24) | 375.4 (± 30.34) |
| QTc interval, Screening, n=5, 8, 5 | 396.6 (± 43.69) | 401.1 (± 24.31) | 402.4 (± 24.69) |
| QTc interval, Day 1: pre-dose, n=5, 9, 5 | 415 (± 22.46) | 401 (± 26.37) | 399.6 (± 25.99) |
| QTc interval, Day 1: 1 hr, n=5, 9, 5 | 409 (± 31.71) | 402.7 (± 32.39) | 373 (± 21.83) |
| QTc interval, Day 1: 4 hr, n=5, 9, 6 | 414.6 (± 23.33) | 392.3 (± 25.5) | 391.8 (± 23.03) |
| QTc interval, Day 29, pre-dose, n=5, 8, 5 | 408.5 (± 26.41) | 395 (± 27.81) | 394.8 (± 26.11) |
| QTc interval, Day 29: 1 hr, n=5, 8, 4 | 405 (± 29.26) | 406.4 (± 29.18) | 391 (± 21.69) |
| QTc interval, Day 29: 4 hr, n=5, 8, 5 | 415.4 (± 20.47) | 401.3 (± 27.59) | 396.8 (± 26.53) |
| QTcB interval, Screening, n=7, 5, 7 | 428.9 (± 66.45) | 438.2 (± 73.43) | 458.7 (± 82.52) |
| QTcB interval, Day 1: pre-dose, n=7, 4, 7 | 446.4 (± 87.83) | 444.5 (± 83) | 450.6 (± 82.8) |
| QTcB interval, Day 1: 1 hr | 425.6 (± 69.63) | 435.8 (± 89.82) | 440 (± 89.05) |
| QTcB interval, Day 1: 4 hr, n=7, 4, 7 | 422.1 (± 69.64) | 441.5 (± 87.44) | 451.5 (± 90.65) |
| QTcB interval, Day 29, pre-dose, n=7, 4, 6 | 429.4 (± 70.44) | 441.5 (± 87.64) | 435.9 (± 87.94) |
| QTcB interval, Day 29: 1 hr, n=7, 5, 8 | 428.4 (± 94.13) | 425 (± 81.65) | 440.6 (± 79.75) |
| QTcB interval, Day 29: 4 hr, n=7, 5, 7 | 422 (± 69.14) | 427.2 (± 80.83) | 441 (± 87.06) |
| QTcF interval, Screening, n=7, 5, 7 | 413.7 (± 44.18) | 416 (± 41.6) | 434.6 (± 54.29) |
| QTcF interval, Day 1: pre-dose, n=7, 4, 7 | 427.9 (± 60.53) | 416.8 (± 48.73) | 427.9 (± 54.86) |
| QTcF interval, Day 1: 1 hr, n=7, 4, 7 | 412.3 (± 45.59) | 415.3 (± 49.45) | 423.3 (± 59.13) |
| QTcF interval, Day 1: 4 hr, n=7, 4, 6 | 408 (± 47.9) | 415 (± 49.99) | 425 (± 61.7) |
| QTcF interval, Day 29, pre-dose, n=7, 4, 7 | 412.4 (± 47.74) | 411.8 (± 54.02) | 415.7 (± 58.11) |

| | | | | |
|--|------------------|------------------|------------------|--|
| QTcF interval, Day 29: 1 hr, n=7, 5, 8 | 417.7 (± 63.81) | 408.4 (± 45.69) | 421.4 (± 53.3) | |
| QTcF interval, Day 29: 4 hr, n=7, 5, 7 | 408.7 (± 44.66) | 406.6 (± 46.65) | 416.6 (± 59.57) | |
| RR interval, Screening, n=7, 5, 7 | 865.7 (± 243.54) | 806.2 (± 285.39) | 778.7 (± 208.89) | |
| RR interval, Day 1: pre-dose, n=7, 4, 7 | 834.9 (± 210.7) | 746.8 (± 250.85) | 783.3 (± 197.1) | |
| RR interval, Day 1: 1 hr, n=7, 4, 7 | 883.3 (± 230.65) | 851.8 (± 347.73) | 865 (± 235.3) | |
| RR interval, Day 1: 4 hr, n=7, 4, 6 | 873.7 (± 239.34) | 771.5 (± 304.19) | 747 (± 188.66) | |
| RR interval, Day 29, pre-dose, n=7, 4, 7 | 842.6 (± 217.13) | 718 (± 219.91) | 813.7 (± 210.22) | |
| RR interval, Day 29: 1 hr, n=7, 5, 8 | 942.9 (± 257.89) | 893 (± 366.89) | 823.3 (± 223.16) | |
| RR interval, Day 29: 4 hr, n=7, 5, 7 | 888.1 (± 237.25) | 825.6 (± 296.3) | 764.4 (± 204.75) | |

Notes:

[58] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[59] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[60] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in glycohemoglobin A1c (% HbA1c) at Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in glycohemoglobin A1c (% HbA1c) at Days 29, 57, and 85 |
|-----------------|--|

End point description:

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a period of time. The Baseline HbA1c value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[61] | 13 ^[62] | 12 ^[63] | |
| Units: Percentage of HbA1c in the blood | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29, n=12, 12, 12 | -0.34 (± 0.281) | -0.2 (± 0.266) | -0.42 (± 0.469) | |
| Day 57, n=11, 13, 12 | -0.6 (± 0.642) | -0.37 (± 0.411) | -0.61 (± 0.768) | |
| Day 85, n=12, 12, 11 | -0.51 (± 0.847) | -0.3 (± 0.541) | -0.86 (± 0.717) | |

Notes:

[61] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[62] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[63] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in fasting blood insulin from the post-mixed meal test (MMT) at pre-meal and 15, 30, 60, 90, 120, 180, and 250 minutes post-meal at Days 29, 57, and 85

| | |
|--|--|
| End point title | Change from Baseline in fasting blood insulin from the post-mixed meal test (MMT) at pre-meal and 15, 30, 60, 90, 120, 180, and 250 minutes post-meal at Days 29, 57, and 85 |
| End point description: The Baseline fasting blood insulin value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. | |
| End point type | Secondary |
| End point timeframe: Baseline; pre-meal; and 15, 30, 60, 90, 120, 180, and 250 post-meal at Days 29, 57, and 85 | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[64] | 13 ^[65] | 12 ^[66] | |
| Units: Picomoles per liter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29: pre-meal, n=12, 13, 11 | -4 (± 35.017) | 26.31 (± 86.065) | 21.27 (± 51.5) | |
| Day 29: 15 minutes (min), n=12, 13, 11 | 62.5 (± 104.377) | 119.08 (± 123.665) | 176.73 (± 220.933) | |
| Day 29: 30 min, n=12, 13, 11 | 120.5 (± 145.435) | 222.46 (± 286.302) | 181.09 (± 166.186) | |
| Day 29: 60 min, n=11, 13, 11 | 204.55 (± 121.089) | 246 (± 279.971) | 272.18 (± 207.174) | |
| Day 29: 90 min, n=11, 13, 11 | 153.27 (± 74.62) | 192.92 (± 267.733) | 160.36 (± 131.839) | |
| Day 29: 120 min, n=11, 13, 11 | 97.64 (± 82.447) | 131.08 (± 182.382) | 91.09 (± 110.921) | |
| Day 29: 180 min, n=12, 13, 11 | 55 (± 58.387) | 36 (± 88.657) | 8.18 (± 68.897) | |
| Day 29: 240 min, n=12, 13, 11 | 22 (± 46.92) | 5.54 (± 63.708) | -21.27 (± 69.11) | |
| Day 57: pre-meal, n=12, 13, 11 | 2.5 (± 21.928) | 12.46 (± 46.699) | -15.82 (± 57.941) | |
| Day 57: 15 min, n=12, 13, 11 | 44 (± 88.896) | 176.77 (± 334.035) | 105.27 (± 94.654) | |
| Day 57: 30 min, n=12, 13, 11 | 156.5 (± 136.329) | 266.31 (± 456.641) | 147.27 (± 141.131) | |
| Day 57: 60 min, n=12, 13, 11 | 211.5 (± 115.586) | 243.69 (± 163.044) | 247.64 (± 212.439) | |

| | | | | |
|--------------------------------|-------------------|--------------------|--------------------|--|
| Day 57: 90 min, n=11, 13, 11 | 168 (± 49.332) | 214.62 (± 128.058) | 205.09 (± 187.116) | |
| Day 57: 120 min, n=12, 13, 11 | 125.5 (± 73.282) | 109.38 (± 104.216) | 131.45 (± 126.156) | |
| Day 57: 180 min, n=12, 13, 11 | 27 (± 58.481) | 21.69 (± 39.462) | 23.45 (± 50.447) | |
| Day 57: 240 min, n=12, 13, 10 | 2.5 (± 33.008) | -18.92 (± 70.605) | -5.4 (± 55.169) | |
| Day 85: pre-meal, n=12, 13, 10 | 1 (± 33.439) | 17.08 (± 60.441) | 10.2 (± 70.316) | |
| Day 85: 15 min, n=12, 13, 11 | 29 (± 39.372) | 94.15 (± 129.901) | 140.73 (± 224.906) | |
| Day 85: 30 min, n=12, 13, 11 | 194 (± 240.223) | 194.77 (± 174.389) | 176.18 (± 221.046) | |
| Day 85: 60 min, n=12, 13, 11 | 174.5 (± 102.479) | 271.85 (± 334.096) | 250.36 (± 180.122) | |
| Day 85: 90 min, n=12, 13, 11 | 151.5 (± 69.036) | 218.31 (± 153.803) | 197.45 (± 131.356) | |
| Day 85: 120 min, n=12, 13, 11 | 140 (± 73.187) | 175.85 (± 206.461) | 129.27 (± 148.076) | |
| Day 85: 180 min, n=12, 13, 11 | 32 (± 60.831) | 28.15 (± 58.654) | 32.73 (± 53.286) | |
| Day 85: 240 min, 12, 12, 11 | 0.5 (± 32.609) | 0 (± 31.955) | 9.82 (± 69.417) | |

Notes:

[64] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[65] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[66] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in C-peptide levels from the post-MMT (MMT) at pre-meal and 15, 30, 60, 90, 120, 180, and 250 minutes post-meal at Days 29, 57, and 85

| | |
|-----------------|---|
| End point title | Change from Baseline in C-peptide levels from the post-MMT (MMT) at pre-meal and 15, 30, 60, 90, 120, 180, and 250 minutes post-meal at Days 29, 57, and 85 |
|-----------------|---|

End point description:

The Baseline C-peptide value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; pre-meal; and 15, 30, 60, 90, 120, 180, and 250 post-meal at Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[67] | 13 ^[68] | 12 ^[69] | |
| Units: Nanomoles per liter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29: pre-meal, n=12, 12, 11 | 0 (± 0.342) | 0.13 (± 0.307) | 0.07 (± 0.45) | |
| Day 29: 15 min, n=12, 12, 11 | 0.34 (± 0.436) | 0.45 (± 0.397) | 0.51 (± 0.757) | |
| Day 29: 30 min, n=12, 12, 10 | 0.68 (± 0.595) | 0.89 (± 0.634) | 0.92 (± 0.86) | |

| | | | |
|--------------------------------|-----------------|----------------|-----------------|
| Day 29: 60 min, n=11, 12, 11 | 1.14 (± 0.617) | 1.08 (± 0.693) | 1.33 (± 0.97) |
| Day 29: 90 min, n=11, 12, 11 | 1.05 (± 0.284) | 1.15 (± 0.573) | 1.11 (± 0.844) |
| Day 29: 120 min, n=11, 12, 10 | 0.92 (± 0.37) | 1.09 (± 0.527) | 1.03 (± 0.672) |
| Day 29: 180 min, n=12, 12, 10 | 0.81 (± 0.438) | 0.6 (± 0.323) | 0.59 (± 0.46) |
| Day 29: 240 min, n=12, 12, 11 | 0.5 (± 0.463) | 0.27 (± 0.329) | 0.31 (± 0.355) |
| Day 57: pre-meal, n=12, 12, 12 | -0.07 (± 0.314) | 0.07 (± 0.341) | -0.23 (± 0.244) |
| Day 57: 15 min, n=12, 12, 11 | 0.21 (± 0.213) | 0.61 (± 0.941) | 0.29 (± 0.349) |
| Day 57: 30 min, n=12, 12, 11 | 0.56 (± 0.369) | 0.85 (± 0.973) | 0.45 (± 0.543) |
| Day 57: 60 min, n=12, 12, 11 | 1.04 (± 0.591) | 1.25 (± 0.583) | 0.92 (± 0.821) |
| Day 57: 90 min, n=12, 12, 11 | 1.1 (± 0.371) | 1.38 (± 0.653) | 1.02 (± 0.89) |
| Day 57: 120 min, n=12, 12, 11 | 1.06 (± 0.435) | 1.09 (± 0.524) | 1.02 (± 0.837) |
| Day 57: 180 min, n=12, 12, 11 | 0.59 (± 0.332) | 0.6 (± 0.43) | 0.53 (± 0.482) |
| Day 57: 240 min, n=11, 12, 10 | 0.29 (± 0.48) | 0.31 (± 0.395) | 0.2 (± 0.41) |
| Day 85: pre-meal, n=12, 12, 11 | -0.01 (± 0.412) | 0.09 (± 0.325) | 0.02 (± 0.422) |
| Day 85: 15 min, n=12, 12, 11 | 0.17 (± 0.413) | 0.45 (± 0.475) | 0.45 (± 0.721) |
| Day 85: 30 min, n=12, 12, 11 | 0.78 (± 0.832) | 0.98 (± 0.725) | 0.65 (± 0.742) |
| Day 85: 60 min, n=12, 12, 11 | 0.96 (± 0.518) | 1.38 (± 0.683) | 1.03 (± 0.624) |
| Day 85: 90 min, n=12, 12, 11 | 1.01 (± 0.499) | 1.48 (± 0.738) | 1.11 (± 0.55) |
| Day 85: 120 min, n=12, 12, 11 | 1.05 (± 0.404) | 1.43 (± 0.856) | 1.08 (± 0.566) |
| Day 85: 180 min, n=11, 12, 11 | 0.6 (± 0.427) | 0.75 (± 0.436) | 0.6 (± 0.361) |
| Day 85: 240 min, n=12, 12, 10 | 0.28 (± 0.358) | 0.33 (± 0.234) | 0.26 (± 0.416) |

Notes:

[67] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[68] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[69] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in weighted mean insulin level (AUC[0-4hrs]) post-MMT on Days 29, 57, and 85

| | |
|-----------------|---|
| End point title | Change from Baseline in weighted mean insulin level (AUC[0-4hrs]) post-MMT on Days 29, 57, and 85 |
|-----------------|---|

End point description:

The weighted mean parameters were derived by calculating the area under the curve (AUC, which reflects the actual body exposure to drug after administration of a dose of the drug) using the trapezoidal rule, and then dividing by the actual relevant time interval (i.e., actual time point [hrs] of the first non-missing observation [in planned time $t_f=0$ hour] minus the actual time point [hrs] of the last non-missing observation [e.g., in planned time for insulin, $t_l=240$ minutes]). Change from Baseline in weighted mean AUC(0-4hrs) post-MMT profiles for insulin was compared between treatment groups using repeated measures analysis with fixed effects for Baseline, visit, and Baseline by visit. The Baseline weighted mean insulin value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[70] | 13 ^[71] | 12 ^[72] | |
| Units: Picomoles per liter | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29 | 10.3 (± 39.145) | -1.13 (± 103.423) | 4.89 (± 68.334) | |
| Day 57 | 12.52 (± 56.021) | -2.11 (± 56.314) | 21.55 (± 68.549) | |
| Day 85 | 12.26 (± 37.965) | 13.16 (± 78.556) | 9.14 (± 61.995) | |

Notes:

[70] - All Subject Population

[71] - All Subject Population

[72] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in weighted mean C-peptide levels (AUC[0-4hrs]) post-MMT on Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in weighted mean C-peptide levels (AUC[0-4hrs]) post-MMT on Days 29, 57, and 85 |
|-----------------|--|

End point description:

The weighted mean parameters were derived by calculating the area under the curve (AUC, which reflects the actual body exposure to drug after administration of a dose of the drug) using the trapezoidal rule, and then dividing by the actual relevant time interval (i.e., actual time point [hrs] of the first non-missing observation [in planned time $t_f=0$ hour] minus the actual time point [hrs] of the last non-missing observation [e.g., in planned time for C-peptide levels, $t_l=240$ minutes]). Change from Baseline in weighted mean AUC(0-4hrs) post-MMT profiles for C-peptide was compared between treatment groups using repeated measures analysis with fixed effects for Baseline, visit, and Baseline by visit. The Baseline weighted mean C-peptide value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[73] | 13 ^[74] | 12 ^[75] | |
| Units: Nanomoles per liter (nmol/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29 | 0.19 (± 0.365) | -0.1 (± 0.302) | -0.09 (± 0.592) | |
| Day 57 | 0.1 (± 0.234) | -0.06 (± 0.327) | -0.24 (± 0.661) | |
| Day 85 | 0.1 (± 0.247) | 0.09 (± 0.374) | -0.16 (± 0.521) | |

Notes:

[73] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in derived measures of insulin sensitivity (homeostasis model assessment [HOMA]-%S) and beta cell function (HOMA-%B) for insulin and C-peptide at Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in derived measures of insulin sensitivity (homeostasis model assessment [HOMA]-%S) and beta cell function (HOMA-%B) for insulin and C-peptide at Days 29, 57, and 85 |
|-----------------|--|

End point description:

The HOMA estimated steady-state beta cell function (%B) and insulin sensitivity (%S), as a percentages of a normal reference population. The HOMA2 Model was developed for insulin sensitivity (HOMA2-%S), where 100% was normal, which is the reciprocal of insulin resistance (100/S%). The Baseline value is defined as the value at Day 1. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Note: In cases in which no participants were analyzed at a particular timepoint/for a particular parameter, "99999" is used to indicate that data are not available. In cases, in which only one participant was analyzed at a particular timepoint/for a particular parameter, "99999" has been used to indicate that no dispersion data (standard deviation of the mean) are available for this single participant.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[76] | 13 ^[77] | 12 ^[78] | |
| Units: Percentage | | | | |
| arithmetic mean (standard deviation) | | | | |
| Insulin HOMA2-%S, Day 29, n=12, 12, 12 | 9.42 (± 35.88) | -10.03 (± 29.411) | -5.33 (± 27.589) | |
| Insulin HOMA2-%S, Day 57, n=12, 12, 12 | 0.39 (± 12.438) | -8.21 (± 41.853) | 4.45 (± 33.226) | |
| Insulin HOMA2-%S, Day 85, n=12, 12, 11 | -3 (± 15.088) | -15.46 (± 54.893) | -6.81 (± 28.723) | |
| Insulin HOMA2-%B, Day 29, n=12, 12, 12 | -1.82 (± 12.091) | 5.42 (± 10.715) | 3.31 (± 18.961) | |
| Insulin HOMA2-%B, Day 57, n=12, 12, 12 | 5.9 (± 21.891) | 6.63 (± 18.161) | 7.5 (± 31.909) | |
| Insulin HOMA2-%B, Day 85, n=12, 12, 11 | 4.24 (± 23.204) | 7.77 (± 24.274) | 7.45 (± 29.459) | |
| C-peptide, HOMA2-%S, Day 29, n=0, 1, 0 | 99999 (± 99999) | -4.6 (± 99999) | 99999 (± 99999) | |
| C-peptide, HOMA2-%S, Day 57, n=0, 1, 0 | 99999 (± 99999) | -3.8 (± 99999) | 99999 (± 99999) | |
| C-peptide, HOMA2-%S, Day 85, n=0, 1, 0 | 99999 (± 99999) | -1.8 (± 99999) | 99999 (± 99999) | |

| | | | | |
|--|-----------------|-----------------|-----------------|--|
| C-peptide, HOMA2-%B, Day 29, n=0, 1, 0 | 99999 (± 99999) | 33.7 (± 99999) | 99999 (± 99999) | |
| C-peptide, HOMA2-%B, Day 57, n=0, 1, 0 | 99999 (± 99999) | 20 (± 99999) | 99999 (± 99999) | |
| C-peptide, HOMA2-%B, Day 85, n=0, 1, 0 | 99999 (± 99999) | -33.5 (± 99999) | 99999 (± 99999) | |

Notes:

[76] - All Subject Population

[77] - All Subject Population

[78] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration-time curve over the dosing interval (AUC[0-tau])

| | |
|--|---|
| End point title | Area under the concentration-time curve over the dosing interval (AUC[0-tau]) |
| End point description: | |
| AUC(0-tau) is derived as a log-transformed plasma GSK1070806 pharmacokinetic (PK) Parameter and was measured after dose 1 and dose 2 of GSK1070806 0.25 mg/kg and GSK1070806 5 mg/kg. AUC reflects the actual body exposure to drug after administration of a dose of the drug. The PK Population is comprised of participants for whom a PK sample was obtained and analyzed. | |
| End point type | Secondary |
| End point timeframe: | |
| From Day 1 until follow-up (up to Study Day 210) | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[79] | 13 ^[80] | 12 ^[81] | |
| Units: ng*hr/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Dose 1, n=0, 11, 12 | () | 1840725 (± 32.5) | 25415627 (± 62.5) | |
| Dose 2, n=0, 13, 12 | () | 2483463 (± 31.3) | 44281604 (± 22.8) | |

Notes:

[79] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[80] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[81] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed concentration (Cmax)

| | |
|--|---------------------------------------|
| End point title | Maximum observed concentration (Cmax) |
| End point description: | |
| Cmax was measured after dose 1 and dose 2 of GSK1070806 0.25 mg/kg and GSK1070806 5 mg/kg. | |
| End point type | Secondary |

End point timeframe:

From Day 1 until follow-up (up to Study Day 210/average of X study days)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|-------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[82] | 13 ^[83] | 12 ^[84] | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Dose 1, n=0, 11, 12 | () | 8361.1 (± 26.8) | 95179.3 (± 69) | |
| Dose 2, n=0, 13, 12 | () | 9692.1 (± 21.9) | 152972 (± 22) | |

Notes:

[82] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[83] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[84] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Time of occurrence of Cmax (Tmax)

| | |
|--|-----------------------------------|
| End point title | Time of occurrence of Cmax (Tmax) |
| End point description: | |
| Tmax was measured after dose 1 and dose 2 of GSK1070806 0.25 mg/kg and GSK1070806 5 mg/kg. | |
| End point type | Secondary |
| End point timeframe: | |
| From Day 1 until follow-up (up to Study Day 210/average of X study days) | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|-------------------------------|-------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[85] | 13 ^[86] | 12 ^[87] | |
| Units: Hours | | | | |
| median (full range (min-max)) | | | | |
| Dose 1, n=0, 11, 12 | (to) | 1.05 (1 to 67.75) | 1.055 (1 to 4.03) | |
| Dose 2, n=0, 13, 12 | (to) | 1.07 (1 to 68.5) | 1.05 (1 to 4) | |

Notes:

[85] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[86] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

[87] - PK Population. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Terminal phase rate constant

| | |
|-----------------|------------------------------|
| End point title | Terminal phase rate constant |
|-----------------|------------------------------|

End point description:

The terminal rate constant is the rate at which the compound disappears more slowly during the terminal phase. The terminal phase rate constant was measured after the second dose of GSK1070806 0.25 mg/kg and GSK1070806 5 mg/kg. Summary statistics are not generated for this parameter as it is utilized for the calculation of other parameters.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 until follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[88] | 0 ^[89] | 0 ^[90] | |
| Units: 1/hr | | | | |
| arithmetic mean (standard deviation) | () | () | () | |

Notes:

[88] - PK Population

[89] - PK Population

[90] - PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Terminal half life (t_{1/2})

| | |
|-----------------|--|
| End point title | Terminal half life (t _{1/2}) |
|-----------------|--|

End point description:

t_{1/2} was measured after the second dose of GSK1070806 0.25 mg/kg and GSK1070806 5 mg/kg.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 until follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|-------------------|-----------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[91] | 12 ^[92] | 12 ^[93] | |
| Units: Hours | | | | |
| geometric mean (geometric coefficient of variation) | () | 554.721 (± 22.7) | 730.386 (± 21.3) | |

Notes:

[91] - PK Population. Only participants available at the specified time points were analyzed.

[92] - PK Population. Only participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Serum levels of free IL-18 and drug-bound IL-18

| | |
|-----------------|---|
| End point title | Serum levels of free IL-18 and drug-bound IL-18 |
|-----------------|---|

End point description:

Summary statistics were not generated for this parameter.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 until follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|-------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[94] | 0 ^[95] | 0 ^[96] | |
| Units: picograms per milliliter (pg/ml) | | | | |
| arithmetic mean (standard deviation) | () | () | () | |

Notes:

[94] - Summary statistics were not generated for this parameter.

[95] - Summary statistics were not generated for this parameter.

[96] - Summary statistics were not generated for this parameter.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in adiponectin and high-sensitivity C-reactive protein (hsCRP) levels at Days 29, 57, and 85

| | |
|-----------------|---|
| End point title | Change from Baseline in adiponectin and high-sensitivity C-reactive protein (hsCRP) levels at Days 29, 57, and 85 |
|-----------------|---|

End point description:

Serum samples were collected for the estimation of adiponectin and hsCRP biomarker levels. Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism. Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Day 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[97] | 13 ^[98] | 12 ^[99] | |
| Units: mg/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Adiponectin, Day 29, n=12, 13, 12 | 0.08 (± 2.021) | -0.62 (± 2.567) | -1.58 (± 5.534) | |
| Adiponectin, Day 57, n=12, 13, 12 | -0.08 (± 2.275) | -0.54 (± 2.933) | 0.25 (± 2.896) | |
| Adiponectin, Day 85, n=12, 13, 12 | 0.67 (± 1.875) | 0 (± 2.236) | 0.42 (± 1.621) | |
| hsCRP, Day 29, n=12, 11, 12 | 3.04 (± 6.577) | 13.96 (± 49.633) | -8.08 (± 20.237) | |
| hsCRP, Day 57, n=12, 11, 12 | 3.47 (± 7.662) | -0.55 (± 1.226) | -8.1 (± 19.414) | |
| hsCRP, Day 85, n=12, 11, 12 | 0.54 (± 2.137) | -0.17 (± 2.311) | -8.06 (± 19.995) | |

Notes:

[97] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[98] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[99] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in HDL cholesterol, LDL cholesterol, and non-esterified fatty acid levels at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Change from Baseline in HDL cholesterol, LDL cholesterol, and non-esterified fatty acid levels at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

Serum samples were collected for the estimation of HDL cholesterol direct, LDL cholesterol calculation, and non-esterified fatty acids biomarker levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[100] | 13 ^[101] | 12 ^[102] | |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| HDL cholesterol, Day 1: 4 hr, n=11, 11, 11 | -0.1 (± 0.096) | -0.1 (± 0.116) | -0.11 (± 0.07) | |
| HDL cholesterol, Day 4, n=11, 12, 11 | 0.07 (± 0.074) | 0.01 (± 0.077) | 0.02 (± 0.119) | |
| HDL cholesterol, Day 9, n=12, 12, 12 | 0.06 (± 0.117) | 0.05 (± 0.134) | 0.06 (± 0.087) | |
| HDL cholesterol, Day 14, n=12, 12, 12 | 0.04 (± 0.118) | 0.06 (± 0.121) | 0.1 (± 0.116) | |
| HDL cholesterol, Day 21, n=12, 12, 12 | 0.07 (± 0.153) | 0.09 (± 0.146) | 0.12 (± 0.215) | |

| | | | |
|---|-----------------|-----------------|-----------------|
| HDL cholesterol, Day 29 pre-dose, n=11, 12, 12 | -0.01 (± 0.13) | 0.04 (± 0.106) | 0.12 (± 0.197) |
| HDL cholesterol, Day 29: 4 hr, n=12, 10, 11 | -0.1 (± 0.134) | -0.01 (± 0.154) | 0.01 (± 0.216) |
| HDL cholesterol, Day 32, n=11, 12, 12 | 0.06 (± 0.174) | 0.05 (± 0.145) | 0.1 (± 0.129) |
| HDL cholesterol, Day 42, n=12, 12, 12 | 0.06 (± 0.167) | 0.06 (± 0.122) | 0.12 (± 0.204) |
| HDL cholesterol, Day 57, n=12, 12, 12 | 0.02 (± 0.114) | 0.08 (± 0.204) | 0.12 (± 0.207) |
| HDL cholesterol, Day 85, n=11, 11, 12 | 0.03 (± 0.19) | 0.08 (± 0.19) | 0.12 (± 0.195) |
| HDL cholesterol, Day 120, n=11, 12, 12 | 0.04 (± 0.164) | 0.12 (± 0.228) | 0.12 (± 0.211) |
| HDL cholesterol, Day 165, n=12, 11, 12 | 0.05 (± 0.191) | 0.12 (± 0.171) | 0.09 (± 0.123) |
| HDL cholesterol, follow-up, n=12, 11, 12 | 0.13 (± 0.161) | 0.09 (± 0.171) | 0.07 (± 0.129) |
| LDL cholesterol, Day 1: 4 hr, n=11, 11, 10 | -0.35 (± 0.217) | -0.36 (± 0.351) | -0.23 (± 0.159) |
| LDL cholesterol, Day 4, n=11, 12, 11 | 0.02 (± 0.268) | 0.1 (± 0.226) | 0.06 (± 0.28) |
| LDL cholesterol, Day 9, n=12, 12, 12 | -0.06 (± 0.426) | -0.08 (± 0.342) | -0.12 (± 0.274) |
| LDL cholesterol, Day 14, n=12, 12, 12 | -0.09 (± 0.564) | -0.09 (± 0.35) | -0.08 (± 0.391) |
| LDL cholesterol, Day 21, n=12, 12, 12 | -0.01 (± 0.58) | 0.02 (± 0.506) | -0.1 (± 0.394) |
| LDL cholesterol, Day 29 pre-dose, n=11, 12, 12 | -0.05 (± 0.389) | -0.06 (± 0.484) | -0.04 (± 0.413) |
| LDL cholesterol, Day 29: 4 hr, n=12, 10, 11 | -0.36 (± 0.508) | -0.37 (± 0.583) | -0.39 (± 0.611) |
| LDL cholesterol, Day 32, n=11, 12, 12 | -0.01 (± 0.553) | -0.16 (± 0.379) | 0.02 (± 0.3) |
| LDL cholesterol, Day 42, n=11, 12, 12 | 0.2 (± 0.357) | -0.1 (± 0.542) | 0 (± 0.325) |
| LDL cholesterol, Day 57, n=12, 12, 12 | 0.23 (± 0.542) | -0.08 (± 0.356) | 0.13 (± 0.407) |
| LDL cholesterol, Day 85, n=11, 11, 12 | 0.25 (± 0.784) | 0.02 (± 0.406) | 0.02 (± 0.507) |
| LDL cholesterol, Day 120, n=10, 12, 12 | 0.14 (± 0.493) | -0.14 (± 0.61) | 0.07 (± 0.475) |
| LDL cholesterol, Day 165, n=12, 11, 12 | 0.2 (± 0.836) | -0.1 (± 0.624) | 0.15 (± 0.613) |
| LDL cholesterol, follow-up, n=12, 11, 12 | 0.31 (± 0.844) | 0.13 (± 0.417) | -0.2 (± 0.967) |
| Non-esterfied fatty acids, Day 29, n=12, 13, 10 | -0.04 (± 0.135) | -0.02 (± 0.177) | 0.01 (± 0.277) |
| Non-esterfied fatty acids, Day 57, n=12, 13, 10 | 0.04 (± 0.212) | 0.07 (± 0.189) | 0.06 (± 0.311) |
| Non-esterfied fatty acids, Day 85, n=12, 13, 10 | -0.01 (± 0.144) | 0.02 (± 0.187) | -0.05 (± 0.35) |

Notes:

[100] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[101] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[102] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in fructosamine level at Days 29, 57, and 85

| | |
|-----------------|---|
| End point title | Change from Baseline in fructosamine level at Days 29, 57, and 85 |
|-----------------|---|

End point description:

Serum samples were collected for the estimation of fructosamine levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Day 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 ^[103] | 12 ^[104] | 10 ^[105] | |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29 | -7.36 (± 25.26) | -10.25 (± 18.489) | -9 (± 19.402) | |
| Day 57 | -4.18 (± 45.751) | -10.17 (± 30.68) | -6.7 (± 23.66) | |
| Day 85 | -1 (± 43.428) | -6.83 (± 23.053) | -8.1 (± 29.622) | |

Notes:

[103] - All Subject Population. Only participants available at the specified time points were analyzed.

[104] - All Subject Population. Only participants available at the specified time points were analyzed.

[105] - All Subject Population. Only participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in glomerular filtration rate (GFR) at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Change from Baseline in glomerular filtration rate (GFR) at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|----------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[106] | 13 ^[107] | 12 ^[108] | |
| Units: mL/min/1.73 m ² | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1: 4 hr, n=11, 10, 11 | -1.18 (± 14.972) | -24.4 (± 19.693) | -18.45 (± 24.411) | |
| Day 4, n=11, 12, 11 | -10.55 (± 13.419) | -12.5 (± 11.39) | -4.18 (± 10.196) | |
| Day 9, n=12, 12, 12 | -8.33 (± 11.484) | -10.83 (± 10.911) | -8.17 (± 12.597) | |
| Day 14, n=12, 12, 12 | -8.5 (± 11.642) | -16.75 (± 10.593) | -4.08 (± 9.307) | |

| | | | | |
|-------------------------------|-------------------|-------------------|-------------------|--|
| Day 21, n=12, 12, 12 | -8.5 (± 12.147) | -14 (± 10.796) | -7.67 (± 13.68) | |
| Day 29 pre-dose, n=11, 12, 12 | -3 (± 12.61) | -4.5 (± 12.236) | -0.75 (± 13.844) | |
| Day 29: 4 hr, n=12, 9, 11 | -9.92 (± 14.494) | -25.89 (± 20.521) | -15.18 (± 21.706) | |
| Day 32, n=11, 12, 12 | -4.64 (± 11.227) | -19.92 (± 8.49) | -3.08 (± 16.082) | |
| Day 42, n=12, 12, 12 | -9.5 (± 12.895) | -16.83 (± 10.223) | -9.42 (± 15.359) | |
| Day 57, n=12, 12, 12 | -8.5 (± 9.968) | -5.08 (± 10.149) | -2.33 (± 11.284) | |
| Day 85, n=12, 11, 12 | -7.75 (± 8.508) | -14.18 (± 9.453) | -5.17 (± 16.297) | |
| Day 120, n=11, 12, 12 | -11.73 (± 13.001) | -17 (± 13.981) | -11.5 (± 17.578) | |
| Day 165, n=12, 11, 12 | -14.58 (± 12.831) | -10.91 (± 13.262) | -9.08 (± 14.669) | |
| Follow-up, n=12, 11, 12 | -13.5 (± 10.975) | -11.91 (± 11.97) | -12.5 (± 17.381) | |

Notes:

[106] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[107] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[108] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in interleukin-6 (IL-6), inducible protein-10 (IP-10), matrix metalloproteinase-9 (MMP-9), intercellular adhesion molecule-1 (IAM-1), and plasminogen activator inhibitor-1 (PAI-1) levels at Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in interleukin-6 (IL-6), inducible protein-10 (IP-10), matrix metalloproteinase-9 (MMP-9), intercellular adhesion molecule-1 (IAM-1), and plasminogen activator inhibitor-1 (PAI-1) levels at Days 29, 57, and 85 |
|-----------------|--|

End point description:

Serum samples were collected to estimate IL-6, IP-10, MMP-9, IAM-1 levels, and plasma samples were collected for the estimation of PAI-1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Day 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|---------------------|-----------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[109] | 13 ^[110] | 12 ^[111] | |
| Units: ng/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| IL-6, Day 29 | 0.83 (± 2.392) | 0.57 (± 2.149) | -1.03 (± 3.034) | |
| IL-6, Day 57 | -0.24 (± 0.934) | 0.42 (± 0.959) | -1.21 (± 2.71) | |

| | | | | |
|------------------------------|--------------------------|--------------------------|--------------------------|--|
| IL-6, Day 85 | -0.04 (± 1.362) | -0.17 (± 1.002) | -0.93 (± 2.819) | |
| Inducible protein 10, Day 29 | 9.34 (± 153.643) | 25.93 (± 137.181) | -71.82 (± 109.09) | |
| Inducible protein 10, Day 57 | -39.36 (± 122.103) | 5.75 (± 135.903) | -57.63 (± 122.93) | |
| Inducible protein 10, Day 85 | -1.29 (± 92.374) | -4.61 (± 115.887) | -80.62 (± 100.406) | |
| MMP-9, Day 29 | -90583.7 (± 237918.2) | -12523.3 (± 292929) | -155023 (± 295290.1) | |
| MMP-9, Day 57 | -13157.9 (± 261712.8) | -83140.8 (± 124294.1) | -108312 (± 315259.2) | |
| MMP-9, Day 85 | 11328.1 (± 148277.1) | 33993.3 (± 272533.5) | -143274 (± 324839.2) | |
| PAI-1, Day 29 | 32889.5 (± 56971.2) | 2692 (± 65526.9) | -15486.5 (± 37095.97) | |
| PAI-1, Day 57 | 14470.7 (± 39216.4) | 5161.77 (± 55823.3) | -14603.6 (± 88836.85) | |
| PAI-1, Day 85 | 13992.3 (± 38433.2) | 24970.6 (± 96291.6) | -14082.4 (± 75656.88) | |
| IAM-1, Day 29 | -648.1 (± 100568.4) | 15984.15 (± 109324.5) | -18708.7 (± 67939.63) | |
| IAM-1, Day 57 | -31678.9 (± 114736.3) | 21330.63 (± 137433.9) | -36358.3 (± 99707.46) | |
| IAM-1, Day 85 | -60516.9 (± 120963.1) | -1197.05 (± 78516.41) | -75448.8 (± 101530.3) | |

Notes:

[109] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[110] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[111] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in lymphocytes biomarker levels at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up

| | |
|-----------------|--|
| End point title | Change from Baseline in lymphocytes biomarker levels at Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up |
|-----------------|--|

End point description:

Change from Baseline is defined as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Days 1 (4 hr post-dose), 4, 9, 14, 21, 29 (pre-dose and 4 hr post-dose), 32, 42, 57, 85, 120, and 165; and follow-up (up to Study Day 210)

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[112] | 13 ^[113] | 12 ^[114] | |
| Units: GI/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1: 4 hr, n=12, 12, 10 | 0.18 (± 0.311) | 0.28 (± 0.357) | 0.36 (± 0.436) | |
| Day 4, n=11, 12, 10 | 0.24 (± 0.403) | 0.17 (± 0.281) | 0.31 (± 0.487) | |
| Day 9, n=12, 13, 11 | 0.26 (± 0.364) | 0.25 (± 0.324) | 0.33 (± 0.734) | |
| Day 14, n=12, 12, 11 | 0.18 (± 0.599) | 0.16 (± 0.43) | 0.31 (± 0.951) | |
| Day 21, n=12, 13, 11 | 0.1 (± 0.429) | 0.22 (± 0.359) | 0.44 (± 0.541) | |
| Day 29 pre-dose, n=12, 13, 11 | -0.05 (± 0.458) | -0.05 (± 0.421) | 0.03 (± 0.365) | |
| Day 29: 4 hr, n=12, 13, 11 | 0.19 (± 0.467) | 0.45 (± 0.582) | 0.4 (± 0.579) | |
| Day 32, n=12, 13, 9 | 0.09 (± 0.498) | 0.1 (± 0.532) | 0.44 (± 0.269) | |
| Day 42, n=12, 13, 11 | -0.06 (± 0.528) | 0.06 (± 0.276) | 0.29 (± 0.553) | |
| Day 57, n=12, 13, 11 | 0.16 (± 0.549) | 0.21 (± 0.269) | 0.28 (± 0.496) | |
| Day 85, n=12, 13, 11 | -0.02 (± 0.497) | 0.13 (± 0.319) | 0.25 (± 0.536) | |
| Day 120, n=10, 13, 11 | 0.22 (± 0.394) | 0.12 (± 0.377) | 0.27 (± 0.448) | |
| Day 165, n=12, 13, 11 | 0.14 (± 0.602) | 0.28 (± 0.304) | 0.47 (± 0.712) | |
| Follow-up, n=12, 13, 11 | 0.14 (± 0.478) | 0.18 (± 0.359) | 0.27 (± 0.649) | |

Notes:

[112] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[113] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[114] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in resistin biomarker levels at Days 29, 57, and 85

| | |
|-----------------|--|
| End point title | Change from Baseline in resistin biomarker levels at Days 29, 57, and 85 |
|-----------------|--|

End point description:

Serum samples were collected to estimate resistin levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Day 29, 57, and 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[115] | 13 ^[116] | 11 ^[117] | |
| Units: micrograms per liter (µg/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 29 | -0.17 (± 3.114) | -0.03 (± 2.045) | -2.22 (± 2.127) | |
| Day 57 | -0.6 (± 1.67) | -0.23 (± 1.383) | -0.36 (± 2.071) | |

| | | | | |
|--------|----------------|----------------|----------------|--|
| Day 85 | 1.44 (± 4.065) | 0.22 (± 1.308) | -0.45 (± 2.07) | |
|--------|----------------|----------------|----------------|--|

Notes:

[115] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[116] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[117] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Albumin/Creatinine Ratio, MCP1/Creatinine Ratio, and HDL/LDL Ratio at Days 29, 57, and 85

| | |
|------------------------|--|
| End point title | Change from Baseline in Albumin/Creatinine Ratio, MCP1/Creatinine Ratio, and HDL/LDL Ratio at Days 29, 57, and 85 |
| End point description: | Change from Baseline was calculated as the post-Baseline value minus the Baseline value, where Day 1 is defined as Baseline. |
| End point type | Secondary |
| End point timeframe: | Baseline; Day 29, 57, and 85 |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--|---------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 ^[118] | 13 ^[119] | 12 ^[120] | |
| Units: Ratio | | | | |
| arithmetic mean (standard deviation) | | | | |
| Albumin/Creatinine Ratio, Day 29, n=11, 13, 9 | -21.55 (± 44.239) | -14.88 (± 34.18) | -3.65 (± 9.827) | |
| Albumin/Creatinine Ratio, Day 57, n=12, 13, 10 | -20 (± 49.537) | -13.89 (± 41.526) | 5.49 (± 12.835) | |
| Albumin/Creatinine Ratio, Day 85, n=12, 13, 11 | -16.1 (± 36.231) | -15.68 (± 38.938) | 1.94 (± 12.017) | |
| MCP1/Creatinine Ratio, Day 29, n=11, 13, 9 | 9.07 (± 22.821) | -21.78 (± 32.329) | -1.02 (± 25.843) | |
| MCP1/Creatinine Ratio, Day 57, n=12, 13, 11 | 2.81 (± 15.518) | -1.4 (± 28.885) | 0.91 (± 18.641) | |
| MCP1/Creatinine Ratio, Day 85, n=12, 12, 11 | -4.48 (± 18.868) | -17.13 (± 11.408) | 0.37 (± 21.605) | |
| HDL/LDL ratio, Day 1:4H, n=11, 11, 10 | 0.07 (± 0.088) | 0.01 (± 0.044) | 0 (± 0.052) | |
| HDL/LDL ratio, Day 4, n=11, 12, 11 | 0.01 (± 0.063) | -0.02 (± 0.029) | -0.01 (± 0.068) | |
| HDL/LDL ratio, Day 9, n=12, 12, 12 | 0.01 (± 0.084) | 0.04 (± 0.039) | 0.08 (± 0.131) | |
| HDL/LDL ratio, Day 14, n=12, 12, 12 | 0.01 (± 0.116) | 0.03 (± 0.051) | 0.04 (± 0.12) | |
| HDL/LDL ratio, Day 21, n=12, 12, 12 | 0.01 (± 0.107) | 0.03 (± 0.065) | 0.04 (± 0.114) | |
| HDL/LDL ratio, Day 29 predose, n=11, 12, 12 | 0.03 (± 0.091) | 0.04 (± 0.067) | 0.04 (± 0.11) | |
| HDL/LDL ratio, Day 29:4H, n=12, 10, 11 | 0.08 (± 0.124) | 0.08 (± 0.087) | 0.1 (± 0.174) | |
| HDL/LDL ratio, Day 32, n=11, 12, 12 | 0 (± 0.131) | 0.05 (± 0.05) | 0.02 (± 0.118) | |
| HDL/LDL ratio, Day 42, n=11, 12, 12 | -0.02 (± 0.062) | 0.04 (± 0.072) | 0.03 (± 0.118) | |

| | | | | |
|--|-----------------|----------------|----------------|--|
| HDL/LDL ratio, Day 57, n=12, 12, 12 | -0.05 (± 0.104) | 0.05 (± 0.099) | 0.09 (± 0.223) | |
| HDL/LDL ratio, Day 85, n=11, 11, 12 | -0.02 (± 0.079) | 0.03 (± 0.072) | 0.07 (± 0.159) | |
| HDL/LDL ratio, Day 120, n=10, 12, 12 | -0.03 (± 0.126) | 0.08 (± 0.078) | 0.04 (± 0.095) | |
| HDL/LDL ratio, Day 165, n=12, 11, 12 | 0.02 (± 0.097) | 0.05 (± 0.08) | 0.05 (± 0.246) | |
| HDL/LDL ratio, follow-up, n=12, 11, 12 | 0.01 (± 0.095) | 0.01 (± 0.068) | 0.1 (± 0.189) | |

Notes:

[118] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[119] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

[120] - ASP. Only participants available at the specified time points were analyzed (n=X, X, X).

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in waist circumference at Day 85

| | |
|---|---|
| End point title | Change from Baseline in waist circumference at Day 85 |
| End point description: Summary statistics were not generated for these parameters. | |
| End point type | Secondary |
| End point timeframe: Baseline; Day 85 | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|--------------------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[121] | 0 ^[122] | 0 ^[123] | |
| Units: centimeters | | | | |
| arithmetic mean (standard deviation) | () | () | () | |

Notes:

[121] - All Subject Population

[122] - All Subject Population

[123] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with detectable levels of anti-GSK1070806 antibodies

| | |
|--|---|
| End point title | Number of participants with detectable levels of anti-GSK1070806 antibodies |
| End point description: | |
| End point type | Secondary |
| End point timeframe: From Day 1 until follow-up (up to Study Day 210) | |

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|-----------------------------|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[124] | 13 ^[125] | 12 ^[126] | |
| Units: participants | | 0 | 0 | |

Notes:

[124] - All Subject Population

[125] - All Subject Population

[126] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in body mass index (BMI) at Day 85

| | |
|-----------------|---|
| End point title | Change from Baseline in body mass index (BMI) at Day 85 |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline; Day 85

| End point values | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg | |
|---|--------------------|--------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[127] | 0 ^[128] | 0 ^[129] | |
| Units: kilograms per meters squared (kg/m ²) | | | | |
| arithmetic mean (standard deviation) | () | () | () | |

Notes:

[127] - All Subject Population

[128] - All Subject Population

[129] - All Subject Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment until follow-up (assessed up to Study Day 210).

Adverse event reporting additional description:

SAEs and non-serious AEs are reported for members of the All Subject Population, comprised of all participants who received study drug.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 16.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Participants received placebo via intravenous (IV) infusion on the Day 1 and Day 29 study visits.

| | |
|-----------------------|-----------------------|
| Reporting group title | GSK1070806 0.25 mg/kg |
|-----------------------|-----------------------|

Reporting group description:

Participants received GSK1070806 0.25 milligrams per kilogram (mg/kg) via IV infusion on the Day 1 and Day 29 study visits.

| | |
|-----------------------|--------------------|
| Reporting group title | GSK1070806 5 mg/kg |
|-----------------------|--------------------|

Reporting group description:

Participants received GSK1070806 5 mg/kg via IV infusion on the Day 1 and Day 29 study visits.

| Serious adverse events | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg |
|---|----------------|-----------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Nervous system disorders | | | |
| VIIth nerve paralysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo | GSK1070806 0.25 mg/kg | GSK1070806 5 mg/kg |
|---|------------------|-----------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 10 / 12 (83.33%) | 12 / 13 (92.31%) | 11 / 12 (91.67%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 13 (15.38%) | 3 / 12 (25.00%) |
| occurrences (all) | 0 | 2 | 3 |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Arterial disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Surgical and medical procedures | | | |
| Tooth extraction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Reproductive system and breast disorders | | | |
| Male sexual dysfunction | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 13 (7.69%) | 2 / 12 (16.67%) |
| occurrences (all) | 1 | 1 | 2 |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal obstruction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Anxiety | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| Muscle rupture | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac disorders | | | |
| Left ventricular hypertrophy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|-----------------|
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 13 (23.08%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 4 | 1 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 13 (23.08%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Amnesia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 13 (7.69%) | 2 / 12 (16.67%) |
| occurrences (all) | 2 | 2 | 2 |
| Toothache | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |

| | | | |
|--|----------------|-----------------|----------------|
| Constipation | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 13 (15.38%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hangnail | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Ingrowing nail | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 13 (7.69%) 1 | 0 / 12 (0.00%) 0 |
| Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 2 / 13 (15.38%) 2 | 2 / 12 (16.67%) 3 |
| Arthralgia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 | 2 / 12 (16.67%) 3 |
| Lumbar spinal stenosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Muscle contracture subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Musculoskeletal chest pain subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Rotator cuff syndrome subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) | 4 / 12 (33.33%) 5 | 3 / 13 (23.08%) 4 | 4 / 12 (33.33%) 8 |
| Urinary tract infection | | | |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Acute tonsillitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulpitis dental | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Gout | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported